Section 3 of 6
Product information and disease description
302 evidence topics · 138 sources
Product description
Phase of product development
Summary: development and regulatory status
- Regulatory status: The company states that it has no products approved for sale and has not generated any product sales. The FDA designated Descartes-08 an orphan drug for the treatment of myasthenia gravis on 11/08/2022 (not FDA approved for the orphan indication), and the company announced Regenerative Medicine Advanced Therapy designation for MG on May 22, 2024. A Rare Pediatric Disease Designation for juvenile dermatomyositis (JDM) was granted in September 2024; the company states that approval in JDM may qualify it for a priority review voucher.
- Special Protocol Assessment: On January 27, 2025, the company announced written agreement from the FDA under the Special Protocol Assessment process on the overall design of the phase 3 AURORA trial, which the company states the FDA determined acceptable to support a future biologics license application (BLA) in MG, subject to the outcome of the trial.
- Earlier development: The company has completed a phase 1/2 trial in MG with phase 1b, phase 2a, and phase 2b portions; phase 2a results were published in the Lancet Neurology in July 2023, phase 2b results were presented in December 2024, and 12-month data were reported in April 2025 and published in Nature Medicine in January 2026. As of December 31, 2025, Descartes-08 had been administered to over 100 patients with MG, multiple myeloma, and other diseases.
- AURORA status: The first participant was enrolled in May 2025 (registry actual study start 2025-05-06). The company describes approximately 100 participants with AChR antibody-positive MG; the registry record last updated 2026-09-01 lists actual enrollment of 128, a status of active, not recruiting, estimated primary completion on 2026-12-30, and estimated study completion on 2027-09-30. The company expects topline data in the first quarter of 2027 and plans a BLA filing in mid-2027, and states that it has expanded its medical affairs and commercial teams for launch readiness.
- Financing: Cash, cash equivalents, and restricted cash were $124.7 million as of September 30, 2026, including the initial $50 million tranche of non-dilutive financing from K2 HealthVentures and $22.8 million raised year to date through the at-the-market program; the company expects these resources to support planned operations, including completion of AURORA, into 2028. The term loan facility provides up to $150.0 million in four tranches, of which $50.0 million had been borrowed as of September 30, 2026, and requires a minimum trailing three-month net product revenue of $40.0 million beginning on January 1, 2029. The accumulated deficit was $857.3 million, and approximately $75.5 million remained available under the at-the-market program. In its full year 2025 results (2026), the company had projected that $126.9 million as of December 31, 2025, would support operations into mid-2027.
- Other indications: The phase 2 TRITON trial in moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome and the phase 1/2 HELIOS trial in children and young adults with autoimmune diseases, including JDM, are ongoing, with data from both expected in the first half of 2027. After topline data from a phase 2 trial in systemic lupus erythematosus in November 2025, the company decided to no longer pursue development in that indication.
Regulatory status: Submission planned; BLA planned for mid-2027
Launch
No evidence found.
Launch readiness: expanded medical affairs and commercial teams
AURORA topline data and BLA timing: first quarter of 2027 and mid-2027
Orphan Drug Designation for myasthenia gravis: designated November 2022
| Field | Quoted record |
|---|---|
| Generic name | “autologous T-cells expressing a chimeric antigen receptor directed against B-Cell maturation antigen” |
| Date designated | “11/08/2022” |
| Orphan designation | “Treatment of Myasthenia Gravis” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Cartesian Therapeutics, Inc.” |
Regenerative Medicine Advanced Therapy designation for myasthenia gravis: granted May 2024
Special Protocol Assessment agreement on the AURORA design: January 2025
Rare Pediatric Disease Designation for juvenile dermatomyositis: granted September 2024
AURORA initiation: first participant enrolled May 2025
Development history: phase 1b, phase 2a, and phase 2b portions of MG-001
Clinical exposure across indications through December 2025
Other indications: myositis (TRITON) and pediatric autoimmune diseases (HELIOS)
Systemic lupus erythematosus: development discontinued after November 2025 topline data
Cash position and runway into 2028, September 2026
Financing: K2 HealthVentures term loan facility and at-the-market program
Cash runway into mid-2027, March 2026, superseded in May 2026
Product information
Generic, brand name and therapeutic class of product
Product description: autologous anti-BCMA CAR-T cell therapy in clinical development
Engineering by mRNA transfection of autologous CD8+ T cells
Nonproprietary name and code name in the NCI Drug Dictionary
| Field | Quoted record |
|---|---|
| Drug dictionary name | “autologous anti-BCMA-CAR-mRNA-transfected CD8+ T lymphocytes” |
| Code name | “Descartes-08” |
| Synonym | “anti-BCMA-CAR-mRNA-transfected autologous CD8+ T cells” |
Manufacturing facility: in-house cGMP facility in Frederick, Maryland
Dosage forms and strengths
Target dose per infusion from a single apheresis: phase 2b
Product supplied as frozen aliquots tested before release: phase 1b/2a
Matched placebo presentation in the phase 2b trial
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
NCI Thesaurus classification
| Field | Quoted record |
|---|---|
| NCI Thesaurus code | “C156706” |
| Preferred name | “Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes” |
| Parent concept | “Anti-BCMA CAR T Cells Preparation” |
| Parent concept | “Autologous CAR-T Cells” |
Indication
Indication under study in AURORA: acetylcholine receptor autoantibody-positive generalized myasthenia gravis
Pharmacology
Mechanism of action
Transient CAR expression from RNA without genomic modification
“Engineering of cells using RNA offers distinct advantages toward this goal by exploiting transient CAR expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This characteristic enables dosing at levels that are immediately therapeutic and that exhibit a built-in proliferative check: CAR RNA degrades during cell division.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As a result, RNA cell therapy can be administered without lymphodepletion and in the outpatient setting, also eliminating the risk of secondary malignancies because no genomic modification occurs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CAR-positive cell load limited by the administered dose
“Since the CAR-encoding mRNA does not replicate together with the activated and proliferating rCAR T-cells, the load of CAR+ cells is determined and limited by the administered dose, and declines over time, potentially enabling more precise PK control over the therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because our approach uses ex vivo T-cell proliferation, it does not require the specific cytokine environment induced by lymphodepletion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only CD8+ T-cells are used for manufacturing since CD4+ T-cells are known for their memory function, rather than direct killing function, which is not relevant to RNA-transfected CAR T-cells that express the CAR molecule over days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Target antigen: BCMA on plasma cells
Proposed mechanism: preferential depletion of BCMA-high plasma cells and a precision immune reset
“Potential mechanisms could involve precision ablation (for example, direct cytotoxicity) or interference (for example, trogocytosis) on the BCMAhi subset comprising pathogenic PCs and other cells such as pDCs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Functionally, therefore, Descartes-08 may preferentially deplete PCs expressing high levels of BCMA, which, in patients with autoimmune disease, is preferential to PCs producing pathogenic autoantibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Directly testing these hypotheses is a clinical challenge in the context of autoimmunity because the key target cells are predominantly located outside of circulation—PCs resident in the bone marrow and activated pDCs and B cells in inflamed tissue or lymphatics11,37,41–43.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mechanism compared with complement inhibitors, FcRn inhibitors, and DNA-based CAR-T cell therapies
“These technologies include FcRn inhibitors and complement inhibitors that directly target circulating antibodies and antibody effector function, respectively; both technologies involve ongoing treatment to maintain effect48–50.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further, emerging T cell therapies often involve lymphodepletion, viral vectors and targeting of CD19 that result in non-specific depletion of B cells and, consequently, immunoglobulins and vaccine titers2,45,46.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Preclinical activity: CAR expression peaks on day 1 and BCMA-positive cells are killed
“To confirm function, the Descartes-08 RNA payload was electroporated into CD8+ T cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CAR RNA was rapidly detected and then gradually waned to baseline (Fig. 1e), consistent with expression that peaked on day 1 (Fig. 1f).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Descartes-08 also efficiently depleted autologous PCs from healthy individuals or patients with MG (Fig. 1h,i and Supplementary Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasmablast BCMA and pDC activation markers after treatment compared with placebo: phase 2b
“Intriguingly, analysis of plasmablasts after Descartes-08 treatment revealed significant reductions in BCMA expression on plasmablasts at month 3 (n = 6) (P = 0.035) compared to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, CD86 was significantly reduced on pDCs at month 1 (n = 11) (P < 0.001) relative to placebo and also trended downward at month 3 (Fig. 3e,f).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interestingly, at month 12, the decrease in CD86 levels persisted among the Descartes-08 cohort (Extended Data Fig. 2), although fewer samples were available at month 12 (n = 7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the changes in activation state, the frequency of plasmablasts and circulating pDCs remained unchanged (Fig. 3g,h), consistent with the normal levels observed at screen (Fig. 3a,b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Autoantibody repertoire and anti-AChR antibody titers: phase 2b
“By contrast, Descartes-08 was associated with a greater change in the autoreactome (r value median = 0.72) compared to placebo (r value median = 0.89) at month 3 compared to day 1; this change persisted through month 6 (r value median = 0.74) (Fig. 3j).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, despite the dramatic changes in autoreactome, we did not observe a significant change in the anti-AChR antibody titer (Fig. 3m).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anti-AChR antibody reductions in the phase 2a portion
Immune cell populations, immunoglobulins, and vaccine titers at month 3 and month 12: phase 2b
“In line with our hypothesis, no significant changes were observed between placebo and Descartes-08 when assessing broad immune populations, including the change in frequency of B cells, T cells, natural killer cells and monocytes (Fig. 4a–e and Supplementary Fig. 8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Likewise, total immunoglobulins (Fig. 4f–h and Extended Data Table 3) and common vaccine titers (Fig. 4i–m and Extended Data Table 4) were preserved at month 3 and month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease-associated cytokines after infusion: phase 2b
“Descartes-08 infusion was not associated with indicators of CAR-T cell therapy-induced inflammation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In particular, IL-6, IL-24, CCL19 and artemin (ARTN), all of which are involved in autoimmunity, decreased at month 3 as well as at month 1 and month 12 for some analytes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, IL-6 is a key indicator of MG severity, and this cytokine was significantly reduced at month 3 in patients receiving Descartes-08 (P = 0.019).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
T cell receptor repertoire after treatment
“TCR sequencing revealed that Descartes-08 increases clonal expansion and contraction compared to placebo (Fig. 6a,b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Together, these data indicate that Descartes-08 alters the TCR repertoire without significantly changing the broader phenotypic composition of the T cell compartment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics
Duration of CAR expression: about 1 week in vitro
“Descartes-08 express anti-BCMA CAR for 1 week, limiting risk of uncontrolled proliferation; produce inflammatory cytokines in response to myeloma target cells; and are highly cytolytic against myeloma cells regardless of presence of myeloma-protecting bone marrow stromal cells, exogenous a proliferation-inducing ligand, or drug resistance including IMiDs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The expression of BCMA CAR on Descartes-08 cells was sustained for approximately 1 week, and gradually declined until 9 days (9d) after thawing following their generation (Fig. 1c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Circulating CAR RNA after infusion: phase 1b/2a
“CAR RNA was detected in peripheral blood 1–2 hours post-infusion and at no other time point (Figure s3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Bone marrow biopsies are not customarily done on MG patients, so bone marrow was not assessed for the presence of CARs or CAR RNA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In accordance with time-restricted expression of RNA-based CAR molecules in vitro18, mRNA detection in our study was transient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Circulating CAR RNA after infusion and at month 3: phase 2b
“Lastly, pharmacokinetic profiling using quantitative real-time polymerase chain reaction (qRT–PCR) revealed large, discrete increases in Descartes-08 RNA levels after infusion that were absent prior to infusion and at later times, such as month 3 (approximately 7 weeks after the final infusion) (n = 19) (Fig. 2f).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although some changes in cytokines associated with Descartes-08 did not persist at month 12, others, such as IL-6 and RANKL, did persist or did not become evident until this time (EN-RAGE, TRAIL and TNFSF14), even though CAR expression persists only for a period of days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CAR expression in circulating T cells one day after infusion in a mouse xenograft model
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Age: adults in the phase 2b trial
“MG-001 part 3 was a prospective, double-blind, multicenter, randomized placebo-controlled phase 2b trial evaluating the safety and clinical activity of Descartes-08, RNA-engineered anti-BCMA CAR-T, in adults with generalized MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pediatric population: HELIOS trial including juvenile myasthenia gravis
Contraception for women of childbearing potential in AURORA
Male contraception in the phase 2b trial
“Male patients were to agree to effective contraception (for example, condoms (male or female) with or without a spermicidal agent, a diaphragm or cervical cap with spermicide, or an intrauterine device) from screening through 14 days after the last dose of Descartes-08.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renal and hepatic impairment: phase 2b exclusion thresholds
Drug/Drug, drug/disease interactions
Effects of other drugs on Descartes-08
Consistent product lots across participants with differing treatment histories: phase 2b
“Despite patients with diversity in antibody serotype and treatment history (see companion paper6), all analyzed lots (n = 35 of 36 patients randomized) exhibited consistent characteristics with favorable viability, CD8+ cell frequencies and CAR expression (Fig. 2b–d).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effects of Descartes-08 on other drugs
Vaccine titers after treatment compared with placebo: phase 2b
Dosing and administration
Dosage
Dose selected in the phase 1b portion and carried into the phase 2a portion
Retreatment course after symptom recurrence
Administration
Leukapheresis, then six once-weekly outpatient infusions without preconditioning chemotherapy
“Patients underwent a single leukapheresis to collect cells used to prepare Descartes-08 (Fig. 2a) and then received six once-weekly infusions of Descartes-08 or placebo in an outpatient setting without preconditioning chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Personalized manufacture from the patient’s own collected cells
Infusion duration, premedication, and post-infusion observation: phase 2b
“Participants were then randomly assigned in a 1:1 ratio to receive intravenous treatment with Descartes-08 or placebo, administered once weekly for 6 weeks as an intravenous infusion over 20 min.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diphenhydramine (or an equivalent) and acetaminophen were administered 30 min before each infusion as premedications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were observed for 1 h after each infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Access and distribution
Centralized in-house manufacture and lot release time of about three weeks
Manufacturing success: participants meeting manufacturing specifications in the phase 2b trial
“Of the 45 patients who met the inclusion criteria, 36 were eligible to be randomized after meeting manufacturing specifications, of whom 20 were assigned to the active Descartes-08 arm, and 16 were assigned to the placebo arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Commercial infrastructure plans
Community clinic administration as a design goal of the product
“To broaden use of CAR T-cells in community clinics and in a frontline setting, we developed a novel CD8+ CAR T-cell product, Descartes-08, with predictable pharmacokinetics for treatment of multiple myeloma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Co-prescribed/Concomitant therapies
Permitted concomitant medications and dose changes in the phase 2b trial
“Permitted concomitant medications for gMG included pyridostigmine, corticosteroids (equivalent to ≤40 mg of prednisone per day), azathioprine, mycophenolate mofetil and complement inhibitors, provided the dose was stable for at least 8 weeks before the first infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No dosing changes were allowed for concomitant MG-specific medications during the study, other than corticosteroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The dose of corticosteroids was not permitted to be increased, but it could be tapered at the site investigator’s discretion after month 6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of Descartes-08 on quality measures
AAN quality measure: immunosuppressive therapy for myasthenic crisis
Product-specific effect on quality measures
No evidence found.
Product comparison
Descartes-08: mechanism, route, dosing schedule, and approval status
Complement C5 inhibitor: Soliris
| Attribute | Prescribing information |
|---|---|
| Product and route | “SOLIRIS® (eculizumab) injection, for intravenous use” |
| gMG indication | “the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive.” |
| Mechanism of action | “Eculizumab, the active ingredient in SOLIRIS, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9.” |
| Adult dosing and interval in gMG | “900 mg weekly for the first 4 weeks, followed by” |
| Adult dosing and interval in gMG, continued | “1,200 mg every 2 weeks thereafter.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2007” |
Complement C5 inhibitor: Ultomiris
| Attribute | Prescribing information |
|---|---|
| Product and route | “ULTOMIRIS® (ravulizumab-cwvz) injection, for intravenous use” |
| gMG indication | “the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.” |
| Mechanism of action | “Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity” |
| Dosing interval | “maintenance doses administered every 4 or 8 weeks, starting 2 weeks after loading dose.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2018” |
Complement C5 inhibitor: Zilbrysq
Neonatal Fc receptor blocker: Vyvgart
| Attribute | Prescribing information |
|---|---|
| Product and route | “VYVGART® (efgartigimod alfa-fcab) injection, for intravenous use” |
| gMG indication | “VYVGART is a neonatal Fc receptor blocker indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).” |
| Mechanism of action | “Efgartigimod alfa-fcab is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Dosing and interval | “The recommended dosage is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks.” |
| Treatment cycles | “Administer subsequent treatment cycles based on clinical evaluation.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2021” |
Neonatal Fc receptor blocker: Vyvgart Hytrulo
| Attribute | Prescribing information |
|---|---|
| Product | “VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase” |
| gMG indication | “generalized myasthenia gravis (gMG)” |
| Mechanism of action | “Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Route | “VYVGART HYTRULO is for subcutaneous use only.” |
| Self-administration | “Prefilled syringe can be administered by patients and/or caregivers.” |
| gMG dosing interval | “Administer in cycles of once weekly injections for 4 weeks.” |
| gMG dose, prefilled syringe | “Prefilled syringe: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase administered over 20 to 30 seconds.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |
Neonatal Fc receptor blocker: Rystiggo
Neonatal Fc receptor blocker: Imaavy
CD19-directed B-cell depleting antibody: Uplizna
Complement C5 inhibitor: Klygefa
Place of product in therapy
Disease description
Definition and etiology
Definition: autoantibody-mediated disorder of neuromuscular transmission
“Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MG is considered a classic example of antibody-mediated autoimmune disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These autoantibodies disrupt cholinergic transmission between nerve terminals and muscle fibers by causing downregulation, destruction, functional blocking of AChRs, or disrupting the clustering of AChRs in the postsynaptic membrane.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other AChR-related proteins in the postsynaptic muscle membrane.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Localized or general muscle weakness is the predominant symptom and is induced by the antibodies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients are grouped according to the presence of antibodies, symptoms, age at onset and thymus pathology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Generalized and ocular forms
“MG presents in two forms: ocular (oMG), affecting the levator palpebrae superioris, orbicularis oculi, and extraocular muscles, and generalized (gMG), involving bulbar, axial, limb, and respiratory muscles” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients have generalized weakness affecting the extraocular, bulbar, trunk, and extremity muscles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 20% of MG patients, the muscle weakness remains confined to the extraocular muscles” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is the prototypic autoimmune disease most commonly caused by antibodies to the acetylcholine receptor (AChR) leading to characteristic fatigable weakness of the ocular, bulbar, respiratory, axial, and limb muscles.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: autoantibody subgroups
“Antibodies against the AChR are found in approximately 80% of MG patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AChR antibodies are predominantly of the IgG1 and IgG3 subclasses” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Antibodies against MuSK are found in approximately 7–10% of all MG patients and up to 40% of patients with generalized MG who are seronegative for AChR Abs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lrp4 antibodies are present in 2–50% of double seronegative MG cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In around 10% of patients with generalized MG, no antibodies are detected by standard testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many of these patients have low‐concentration or low‐affinity AChR antibodies when tested with more sensitive methods” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: thymus pathology and age at onset
“Most MG patients have pathogenic autoantibodies against the extracellular part of acetylcholine receptors (AChR), commonly associated with an abnormal thymus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thymoma is present in 10% of such patients, and thymic hyperplasia with ectopic germinal centers appears in most patients with symptom onset before age 50 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Early-onset MG (EOMG) corresponds to patients presenting before age 50.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Late-onset MG (LOMG) is defined by onset after the age of 50.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MG is the most common paraneoplastic disorder associated with thymoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conversely, 10–20% of patients with MG have thymomas” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: genetic susceptibility
“There is frequent association of A1-B8-DR3 haplotype with early-onset MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A large genome-wide association study involving patients from North America and Italy identified different haplotypes across the HLA region, cytotoxic T-lymphocyte-associated protein 4 gene (CTLA4) and tumor necrosis factor receptor 4 superfamily, member 11a, (TNFRSF11A) and NFκB activator genes in early- and late-onset MG cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Generalized myasthenia gravis
United States, 2021 claims and electronic health records: incidence of all myasthenia gravis
“Data were extracted from the Clarivate Real-World Data Repository (2016-2021), a US claims and electronic health records database.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While the incidence and prevalence of MG increased with age in both men and women, higher prevalence and incidence of MG were observed in younger women (<50 years) compared with men of matching age, and in older men (≥65 years) compared with women of the same age group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States, 2017 commercial, Medicare, and Medicaid claims: incidence of all myasthenia gravis
“From the US commercially/Medicare-insured cohort, we calculated an age-and sex-standardized incidence of 68.5 new cases per million person-years with an adjusted prevalence of 316.4 per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within the Medicaid-insured population, similar yet slightly lower numbers emerged: the adjusted incidence was 49.7 new cases per million person-years, and the adjusted prevalence rate was 203.7 cases per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We extrapolated this to calculate the overall US prevalence of 320.2 per million people and an incidence of 54 per million person-years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States, Medicare fee-for-service beneficiaries aged 65 years and older: incidence of all myasthenia gravis, 2008 to 2019
“Study-eligible beneficiaries were aged 65 years and older, had at least 1 month of FFS Part A/B coverage, and were without any health maintenance organization insurance coverage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MG incidence increased from 12.2 to 13.3 per 100,000 PYs from 2008–2009 to 2018–2019 (p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Taiwan, 2009 to 2019: incidence of generalized myasthenia gravis
“There was no temporal trend in all-cause fatality rates (range 2.76–3.79/100 patients annually) or gMG incidence rates (2.4–3.17/100,000 population annually).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 2019, the annual prevalence of gMG was 11.18 per 100,000 population and the incidence rate was 2.95 per 100,000 population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Canada, Ontario, 2013 to 2020: incidence of all myasthenia gravis
Global systematic review of studies through February 2024: incidence of all myasthenia gravis
“Incidence rates ranged from 2.3 to 61.3 cases per million person-years, with a mean incidence of 15.7 (95% CI: 11.5–19.9) and a median of 13.3 cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies showed increasing rates over the years (Fig. 4): considering the period 1967–2007, the mean IR was 8.7 (95% CI: 5.5–11.9; range: 2.3–21.3) cases per million person-years, and in the period 2008–2022, the mean IR has more than doubled: 22.9 (95% CI: 14.1–31.7; range: 6.3–61.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The American countries showed the highest mean IR cases per million person-years with a value of 23.7 (95% CI: 6.5–40.9; range: 4.7–61.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled analysis of 55 studies performed from 1950 to 2007: incidence of all and AChR antibody-positive myasthenia gravis
“55 studies performed between 1950 and 2007 were included, representing 1.7 billion population-years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IR ranged from 1.7 to 21.3 cases per million person-years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled estimate IR (eIR) was calculated as 5.3 per million person-years (C.I.: 4.41 - 6.12).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AChR MG IR ranged from 4.3 to 18.0 per million person-years with a pooled AChR MG eIR of 7.3 per million person-years (C.I.: 5.5, 7.8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Generalized myasthenia gravis
United States, 2021 claims and electronic health records: diagnosed prevalence of all myasthenia gravis
“The diagnosed prevalence and incidence of MG in the United States in 2021 were calculated to be 37.0 per 100,000 persons and 3.1 per 100,000 persons, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The updated prevalence and incidence of MG in the United States in 2021 are higher than previous reports from the 1980s and early 2000s, following a global trend of increased prevalence and incidence for this disorder in the last few decades.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States, 2017 claims and 2021 extrapolation: prevalence and number of adults with all myasthenia gravis
“Using a previously validated algorithm, we identified cases of MG in two Truven Health MarketScan databases, which during 2017 included a sample of approximately 20 million commercially insured and Medicare recipients, plus 10 million Medicaid recipients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given our results, we were able to estimate that there were approximately 82,715 US adults living with MG in 2021 (or an estimated 320.2 cases per million adults in the USA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States, Medicare fee-for-service beneficiaries aged 65 years and older: prevalence of all myasthenia gravis, 2006 to 2019
“The period prevalence of MG increased from 81 to 119 per 100,000 FFS A/B population from 2006–2007 to 2018–2019 (p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing trends of prevalence were observed in all sex (male/female), age (65–69/70–74/75–79/80+), race/ethnic (African American/Asian/Hispanics of any race/non-Hispanic White/other), and census region (Northeast/Midwest/South/West) subgroups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global meta-analysis of 63 studies: prevalence of all myasthenia gravis
“After deleting articles unrelated to the research question, finally, 63 articles with a sample size of 1,206,961,907 people were included in the meta-analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of MG worldwide was estimated to be 12.4 people (95% CI 10.6–14.5) per 100,000 population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“which has the highest prevalence in the Americas with 19 people (95% CI 15–23.8)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global systematic review of studies through February 2024: prevalence of all myasthenia gravis
“Prevalence of MG ranged from 20 to 475 cases per million, with a mean prevalence of 173.3 (95% confidence interval [CI]: 129.7–215.5) cases per million and a median prevalence of 129.6 cases per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean PR was 97.5 (95% CI: 59.9–141.9; range: 20–174.2) cases per million considering studies from 1952 to 2007 (the most recent period investigated by the last systematic review [7]), while the mean PR increased up to 220.1 (95% CI: 149.3–288.1; range: 78–475) cases per million considering the period 2008–2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“North America showed a mean PR of 341.4 (range: 142–475) cases per million” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most of the included studies (81.9%) examined all types of MG (ALL MG), reporting prevalence (59 studies), incidence (50 studies), and mortality (16 studies).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled estimate across studies: prevalence of all myasthenia gravis
“The observed PR ranged from 15 to 179 per million” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated pooled PR is 77.7 cases per million (C.I.: 63.98, 94.30) but, as for IR there was marked heterogeneity with I2 = 98% (C.I.: 97-98%) observed across studies limiting interpretation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Taiwan, 2009 to 2019: prevalence of generalized myasthenia gravis
“The number of patients with gMG increased from 1,576 in 2009 to 2,638 in 2019 and the mean (standard deviation) age from 51.63 (17.32) to 55.38 (16.29) years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of patients with gMG increased annually from 6.83/100,000 population in 2009 to 11.18/100,000 population in 2019 (p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The total number of patients with MG (ocular or generalized) increased from 3,647 in 2009 to 6,293 in 2019, with prevalence rates that increased annually from 15.80 per 100,000 population to 26.67 per 100,000 population, a 1.7-fold increase over the study period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Canada, Ontario, 2013 to 2020: prevalence of all myasthenia gravis
United States, ICER budget impact inputs: number of people with generalized myasthenia gravis (MGFA class II to IV)
Share of myasthenia gravis that becomes generalized and share of generalized disease with AChR antibodies: ICER review
Antibody status of generalized myasthenia gravis: Spanish referral cohort of 220 participants diagnosed 1998 to 2020
Natural history, survival, and mortality
Natural history: progression from ocular to generalized disease
“In addition, up to 80% of patients with ocular onset will go on to develop generalized symptoms, usually within two years of disease onset” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A recent population-based study conducted by the Mayo Clinic found that 51% of patients presented with ocular onset, and 55% of these developed generalized symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the remaining, 90% will continue to have ocular manifestations only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hence, ocular MG is defined by isolated extra-ocular involvement for a period of ≥2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: severity peaks early, and exacerbations recur
“Between 1940 and 2000 a total of 1976 patients with myasthenia gravis (MG) were studied.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most severe level of weakness and high mortality occurred during the first 1 to 2 years of the disease, after which many patients experienced improvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: spontaneous remission
“Spontaneous remissions for different lengths of time may occur in the course of adult-onset MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In an earlier study conducted before the widespread use of steroids and other immunosuppressants, approximately one fourth of the patients had a complete or near complete spontaneous remission, lasting an average of 4.6 years and up to 17 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Half of the remissions occurred during the first year after onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality rates across studies: pooled mean and range
“showing a mean MR of 1.4 (95% CI: 0.8–2.1; range: 0.5–3.5) cases per million person-years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No trend was observed for MR over the years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: United States hospitalizations, 2000 to 2005
“The overall in-hospital mortality rate was 2.2%, being higher in MG crisis (4.47%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Older age and respiratory failure were the predictors of death, with adjusted odds ratios of 9.28 (95% confidence interval [CI], 3.31, 26.0) and 3.58 (95% CI, 2.01, 6.38).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality and survival: United States Medicare beneficiaries aged 65 years and older
“All-cause mortality among MG beneficiaries was stable from 6.26 deaths per 100 PYs in 2006–2007 to 5.67 in 2018–2019 (p = 0.18).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cohorts of 6024 incident MG and 30,083 control beneficiaries were Included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mortality rate was higher in the MG cohort compared to controls (66.8 vs. 57.1 per 1000-person-year, p < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After adjusting for time-varying CCI, no significant difference in survival was observed between two cohorts (adjusted hazard ratio 1.09 [0.87-1.36], p = 0.47).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sixteen percent of deaths in the MG cohort were attributed to MG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to the non-MG cohort, mortality rates (per 1000-person-year) specific to infections were higher among the MG cohort (2.0 vs. 1.2) while malignancies and dementia-specific mortality rates were lower (10.3 vs. 12.5 and 4.7 vs. 7.2), all p < 0.01.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: Denmark nationwide cohort, 1985 to 2020
“Our cohort encompassed 2,110 patients (50.2% female) and 21,100 from the general population, with 77.3% aged younger than 75 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Short-term cumulative mortality was 4.8% in patients with MG and 2.6% in the general population, yielding a HR of 1.8 (95% CI 1.5-2.3). Long-term mortality was 1.3 (95% CI 1.1-1.5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Comorbidity-adjusted analyses decreased short-term mortality (HR 1.6, 95% CI 1.3-2.0), and long-term mortality aligned with the general population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: Taiwan, generalized myasthenia gravis, 2009 to 2019
Survival: Ontario, Canada, with and without myasthenic crisis
Mortality: Israel, tertiary center cohort, 2000 to 2023
“Myasthenia Gravis mortality was 14% at 5 years (61/422) and 21% at 10 years (87/422).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mortality was significantly higher than control groups (p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intubations during myasthenic crisis were linked to higher mortality (p = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Neuromuscular junction: reduced acetylcholine receptors and sodium channels
“In addition, there is a reduction in the number of AChRs and voltage-gated sodium channels as the result of complement-related injury to the postsynaptic membrane in MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The resultant inefficient neuromuscular transmission is reflected in decremental response in the amplitude of compound muscle action potential (CMAP) during repetitive nerve stimulation (RNS) and abnormal jitter or blocking in single fiber EMG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AChR antibodies: complement fixation, antigenic modulation, and receptor blockade
“The predominant mechanism is the binding of the antibody and activation of the complement cascade, leading to the formation of the membrane attack complex (MAC), which causes damage of the postsynaptic membrane and destruction of synaptic folds which contain AChRs and associated proteins, including voltage-gated sodium channels” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other mechanisms of pathogenicity include: (1) antigenic modulation by the binding and crosslinking of AChRs, leading to increased endocytosis and degradation [37]; and (2) the impairment of AChR function, either by the blocking of ACh binding to the receptor [38] or the prevention of channel opening” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anti-AChR autoantibodies belong to the IgG1 and IgG3 subclasses, that are the strongest activators of the complement system.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Indeed, pathogenicity of these autoantibodies, but not that of anti-MuSK antibodies that belong to IgG4, is mainly due to complement fixation at the NMJ ultimately leading to postsynaptic membrane destruction and impairment of the neuromuscular transmission” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement: classical pathway initiation at the endplate
“In MG, complement-mediated damage of the NMJ occurs via the classical complement pathway, which starts with C1q binding to the Fc domain of the autoantibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Critical steps of the complement cascade are then the cleavage of C3 into C3a and C3b, and of C5 in C5a and C5b, the latter leading to the formation of the membrane attack complex (MAC, C5bC6C7C8C9 also known as C5b-9) that causes focal lysis of the post-synaptic membrane, disruption of post-junctional folds, and ultimately reduction of functional AChRs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In MG, the classical pathway is involved by the initiation of the antigen/antibody complex being recognized by C1q.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The C1q forms a pentameric complex with the C1r2C1s2 serine protease tetramer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C2 also becomes cleaved by C1s to form the C3 convertase (C4b2a).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement: deposition at the endplate in patients
“In muscle biopsies from MG patients, IgG and C3 deposition was localized at identical sites of post-synaptic membrane, and specifically on debris of junctional folds in the synaptic clefts and disintegrating junctional folds” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Deposition of C9, the main component of the final and stable MAC, was also observed at the MG end plate regions, with the most intense depositions associated with the destroyed NMJs, indicating that NMJ loss may be largely due to complement activation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with anti-AChR+ MG have autoantibodies and MACs present at NMJs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Damaged NMJs are associated with more severe disease, fewer AChRs, and MACs in synaptic debris.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Complement: evidence from experimental autoimmune myasthenia gravis
“Mice deficient in C3 and C4 demonstrate reduced clinical scores compared to their wild-type littermates during the course of active EAMG, with C3-knockout mice showing no signs of weakness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Complement-deficient EAMG animals showed a preservation of AChR density at the neuromuscular junction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C5-deficient mice demonstrated reduced incidence of disease compared to the C5-sufficient mice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies in animals lacking specific complement proteins have confirmed that MAC formation is required to induce experimental autoimmune MG (EAMG) and NMJ damage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Complement inhibition in EAMG models can prevent disease induction and reverse its progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Complement: C1s and classical pathway activation in patients
“The C1-inhibitor (C1-INH) regulates the classical pathway and is a promising marker in other autoimmune disorders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Serum and plasma C1s-C1-INH levels were higher in MG patients than in matched healthy controls, supporting early classical pathway activation in most MG patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These findings allow prospective validation studies of activated C1s as a putative treatment target and potential accompanying biomarker in MG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Circulating complement protein profile may be used as a biomarker for evaluating patient-specific complement activation: (i) Romi and colleagues found reduced C3 and C4 serum levels in AChR-MG patients with high autoantibody titers, indicating increased in vivo complement consumption” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement: heterogeneity of complement dependence and response to C5 inhibition
“By means of this system, they observed a subset of AChR-MG patients with high complement activity, who are likely patients in whom complement activation is the major disease mechanism, whereas the remaining patients showed low activity, reflecting possible complement-independent autoantibody-mediated mechanisms of NMJ damage” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MuSK and LRP4 antibodies: complement-independent mechanisms
“MuSK antibodies belong mainly to the IgG4 subclass.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“They do not fix complement and are not strong activators of cell-mediated cytotoxicity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mechanism by which MuSK antibodies exert their pathogenic effect on the neuromuscular junction is via binding to the Ig-like domain of the protein, preventing its phosphorylation, and subsequently disrupting the Agrin-Lrp4-MuSK-Dok-7 signaling pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The LRP4 antibodies are primarily IgG1 and IgG2 subtypes and follow similar clinical presentation to a mild form of early-onset MG (22), inhibit clustering of AChR, and appear not to strongly activate complement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Clinical diagnosis and confirmatory testing
“The diagnosis of autoimmune Myasthenia Gravis (MG) remains clinical and rests on the history and physical findings of fatigable, fluctuating muscle weakness in a specific distribution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ancillary bedside tests and laboratory methods help confirm the synaptic disorder, define its type and severity, classify MG according to the causative antibodies, and assess the effect of treatment objectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diagnosis is straightforward in most patients with typical symptoms and a positive antibody test, although a detailed clinical and neurophysiological examination is important in antibody-negative patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Antibody testing: AChR antibodies
“In a patient with clinical features of MG, serum testing for AChR-Ab is the first recommended step in diagnosis by most recent guidelines and expert opinions” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The test has a very high specificity, so the detection of elevated titers in the appropriate clinical setting is diagnostic of AChR-myasthenia, and further testing may not be necessary” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The RIPA for binding Ab is abnormal in up to 85% of adult patients with generalized MG, but only about 50% of patients with ocular MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The technique detects autoantibodies to clustered AChR in about 15% of RIPA-seronegative MG patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibody testing: MuSK and LRP4 antibodies and seronegative disease
“MuSK-Ab are found in about 6–8% of all MG cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In approximately 15% of patients with generalized MG and 50% of patients with ocular MG, both AChR and MuSK antibodies were absent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Detection rates in double-seronegative patients range from 2% to 50%, depending on the geographical origin, with LRP4-Ab being more frequent in non-Caucasian patients, and on the employed assay, with Live CBA being the most widely used” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibody testing: United States testing patterns after a new diagnosis
“Of 5788 cases, 2590 (44.7 %) had at least one valid serology test result: 1453 (56.3 %) seronegative, 1094 (42.4 %) anti-AChR+, 28 (1.1 %) anti-MuSK+, and 5 (0.2 %) anti-LRP4+.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among the seronegative, 56.6 % were only tested for anti-AChR antibodies, 33.7 % tested both anti-AChR and anti-MuSK antibodies, and 5.0 % tested all three antibodies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Electrodiagnosis: repetitive nerve stimulation
“In generalized MG, RNS of distal muscles is abnormal in 30–35% of patients, while in proximal muscles, it is abnormal 60–70%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One should note as a standard feature the high specificity of RNS, which reaches about 97% in generalized MG and 94% in ocular MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Electrodiagnosis: single-fiber and concentric needle jitter
“The jitter study is the most sensitive indicator of impaired neuromuscular transmission” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CNE jitter is abnormal in 98–100% in generalized MG and above 90% in ocular MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While highest in sensitivity, jitter measurements are not specific and may be abnormal in other synaptic disorders, in denervation and reinnervation processes (poly- and mononeuropathies), some myopathies, and with motor neuron disorder (MND) in particular” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bedside tests: ice-pack and edrophonium tests
“The test is used mostly in ocular MG and seems more popular among neuro-ophthalmologists; some authors report sensitivities equal to that of single-fiber electromyography (SFEMG) in patients presenting with ptosis and a very high negative predictive value” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, others note much lower specificity at about 25%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the USA, edrophonium has been discontinued since 2018” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MGFA clinical classification
Consensus definitions: minimal manifestation status, impending crisis, and crisis
“MMS: The patient has no symptoms or functional limitations from MG but has some weakness on examination of some muscles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rapid clinical worsening of MG that, in the opinion of the treating physician, could lead to crisis in the short term (days to weeks).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Worsening of myasthenic weakness requiring intubation or noninvasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay: United States patients with generalized myasthenia gravis
“Quantitative surveys and qualitative interviews were conducted (January-May 2023) in patients with gMG (n = 71 surveys; n = 47 interviews) and clinicians in the United States treating patients with gMG (n = 12 surveys and interviews).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients had mean (SD) diagnostic journey time of 11.8 (22.5) months from symptom onset to seeking care and 15.5 (36.7) months from seeking care to diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sources of diagnostic journey delay (≥9.9 % patients) were: clinicians mistaking gMG symptoms as female health issues, difficulty accessing specialty care, and lack of gMG knowledge among HCPs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Core feature: fatigable, fluctuating, predominantly proximal weakness
“The core clinical manifestation of MG is fatigable muscle weakness, worsened by exertion and improved by rest.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Muscle weakness fluctuates over time and increases with repeated or sustained muscle use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The weakness is more pronounced in proximal than distal muscles, and leg muscles are typically mildly weak or unaffected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The weakness is symmetrical, apart from the eyes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ocular symptoms: ptosis and diplopia
“The most common presenting symptoms are ocular, with double vision and ptosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients will develop diplopia and/or ptosis some time during the course of their disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bulbar symptoms: dysarthria, dysphagia, and facial and jaw weakness
Axial symptoms: neck weakness and head drop
“Axial weakness can also be present, with neck flexion weakness usually more common than weakness of neck extension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a previous retrospective study from our center, about 10% of MG patients developed head-drop some time during the disease course” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Head-drop was associated with age >60 and male patients in that study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limb symptoms: proximal and, less often, distal weakness
“Limb muscle weakness tends to be symmetric and proximal, and patients commonly complain of difficulty climbing stairs, getting up from chairs, and raising arms above their head.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In some instances, distal muscles can be predominantly affected, either in a symmetric or asymmetric distribution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported symptoms: frequency and most bothersome symptoms
“Semi-structured, in-depth concept-elicitation interviews were conducted with 28 individuals diagnosed with gMG in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants reported gMG symptoms that affected many body regions and functions, with an average of 16 symptoms per participant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequently reported symptoms were eyelid drooping (93%), physical fatigue (89%), symptoms affecting the legs (82%), difficulty breathing (82%), and difficulty holding head up (82%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants’ most bothersome symptoms were blurry/double vision (43%), breathing difficulties (36%), all-over fatigue (36%), and swallowing problems (29%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Symptoms by antibody subgroup: MuSK antibody-positive disease
“Muscle weakness preferentially affects cranial and bulbar muscles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over 40% of patients present with bulbar weakness, usually associated with neck and respiratory involvement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“About 30% of patients present with diplopia and/or ptosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limb weakness can be uncommon, but when present it tends to be severe and associated with muscle atrophy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Myasthenic crisis: frequency, triggers, and outcomes
“Myasthenic crisis (MC) is a life-threatening manifestation of myasthenia gravis (MG) defined by respiratory insufficiency that requires the use of invasive or non-invasive ventilation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MC occurs in approximately 15%-20% of patients with MG usually within the first 2 to 3 y of the disease course.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Many crises have a specific trigger with respiratory infections being most common; however, no specific trigger is found in 30%-40% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MG patients with a history of MC, severe disease, oropharyngeal weakness, muscle-specific kinase (MuSK) antibodies and thymoma appear to be at higher risk.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mortality rate in United States cohorts is less than 5% and mortality in MC seems to be driven by age and other medical co-morbidities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A myasthenic crisis (MC) is a more severe, life-threatening escalation of muscle weakness that leads to respiratory failure, necessitating intensive care unit admission with assisted ventilation, usually requiring an inpatient stay period of several weeks, often in the range of 2–4 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 20% of patients with gMG are estimated to experience MC during a period of 3 years or longer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Myasthenic crisis: Ontario, Canada, population-based incidence
Exacerbations and crises: predictors, United States generalized myasthenia gravis
“Among 6,195 patients with gMG (mean age: 61.1 years; female: 49.1%), higher event risk was associated with use of immunoglobulin [hazard ratio (HR) = 1.54], baseline dysarthria (HR = 1.45), general and other muscle-specific weaknesses (HR = 1.38), use of non-steroidal immunosuppressants (HR = 1.37), dysphagia (HR = 1.28), weight loss (HR=1.27), dyspnea (HR = 1.23), ptosis (HR = 1.20), absence of other autoimmune disorders (HR=1.18), and male sex (HR = 1.15; all p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Refractory disease: persistent moderate or severe weakness
Glucocorticoid toxicity: United States commercially insured adults with generalized myasthenia gravis
“Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the study period, incident GC toxicities were more common among patients in the any GC use cohort than the no GC use cohort (61.9% vs 52.3% with ≥1 toxicity), with a trend of increasing incidence with increasing GC use (≥5 mg/d: 62.9%; ≥10 mg/d: 67.3%; all P < .001” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, a greater proportion of patients with any GC use than no GC use had ≥3 incident GC toxicities (16.5% vs 9.5%), with this proportion rising with mean PEDD ≥5 mg (18.9%) and mean PEDD ≥10 mg (22.8%; all P <.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both acute and chronic incident GC toxicities were more common in the any GC use cohort than the no GC use cohort (acute: 28.5% vs 19.1%; chronic: 51.9% vs 43.8%; both P <.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since claims data do not contain reasons for diagnoses, toxicities could not be confirmed to be related to GC use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoid toxicity: recognized adverse effects and higher-risk patients
Refractory disease: share and crisis rates in U.S. administrative health plan data
“Rates of myasthenic crises, exacerbations, inpatient hospitalizations, and emergency room (ER) visits over a 1-year period were measured for 403 refractory, 3,811 nonrefractory, and 403 non-MG control patients from two administrative health plan databases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with nonrefractory patients, a significantly greater percentage of refractory patients had at least one myasthenic crisis (21.3% vs. 6.1%; P < 0.001) and at least one exacerbation (71.2% vs. 32.4%; P < 0.001) over a 1-year period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Refractory disease: share and characteristics in a U.S. tertiary neuromuscular clinic, 2003 to 2011
“A retrospective chart review was completed of 128 MG patients referred to a tertiary neuromuscular clinic from 2003 to 2011.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nineteen out of 128 patients were classified as refractory (14.8 percent). Compared to the non-refractory patients, the refractory patients were more likely to be younger at onset, female, thymomatous, and MuSK-antibody positive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Refractory disease: share assumed in the ICER evaluation
Persistently uncontrolled disease over 8 years of follow-up: Spanish referral cohort
“The proportion adequately controlled (AC) patients increased from 62.0% at 2 years after first visit to 81.9% after 8 years of follow-up. 47.3% of patients remained AC in every observation, and 17.7% remained not adequately controlled (NC) in every observation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AE-related drug interruption rates were higher in NC patients (ranging from 50% to 100% during the study).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Generalized myasthenia gravis
Humanistic burden and health-related quality of life
Patient-reported burden by MGFA class: MyRealWorld MG baseline, seven countries
“Adult patients with MG from seven countries (USA, Japan, Germany, UK, Italy, Spain and Canada) downloaded a mobile application onto their phones and entered data about themselves and their MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline results of 841 participants (mean age 47 years, 70% women) are reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MGFA class was a strong predictor of all aspects of HRQoL, measured with disease-specific and with generic instruments. The domains in which patients with MG most frequently mentioned problems were usual activities, anxiety and depression, tiredness, breathing and vision.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean baseline EQ-5D-5L utility was also associated with MGFA classes and was 0.817, 0.766, 0.648 and 0.530 for MGFA class I–IV.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MG has a large impact on key aspects of health and HRQoL. The impact of this disease increases substantially with increasing disease severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health utilities and medical care use compared with the general population
“In MRW ( n = 1859), 58.4% of respondents had moderate-to-severe MG. Average utility values were lower in MRW versus POPUP (0.739 vs. 0.843 for EQ-5D-5L; 0.493 vs. 0.746 for HUI3), and declined with more severe disease (0.872, 0.707, 0.511 EQ-5D-5L utilities and 0.695, 0.443, 0.168 HUI3 utilities for mild, moderate, and severe MG, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Use of medical care was twice as likely in MRW in comparison with POPUP (51.9% vs. 24.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life and support needs in U.S. adults receiving standard of care without advanced biologics
“Patients had received treatment with standard of care (acetylcholinesterase inhibitors, non-steroidal immunosuppressants, corticosteroids, rituximab, immunoglobulins, plasmapheresis) but not advanced biologics (eculizumab, ravulizumab, zilucoplan, efgartigimod, rozanolixizumab, nipocalimab).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 157 eligible patients completed the survey (87.3% female, mean [SD] age 49.5 [14.4] years, mean [SD] time since diagnosis 11.0 [10.9] years). Mean (SD) MG-QoL-15R score was 16.2 (7.2), EQ5D-5L score was 0.6 (0.3), and FACIT-fatigue subscale score was 20.2 (11.3). Overall, 51.6% received additional support/care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with moderate/severe gMG (136/157 [86.6%]) had greater symptom occurence, reduced treatment satisfaction, greater health-related quality of life impairment, and greater support/care needs, compared with patients with mild gMG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Life domains affected in U.S. patients and caregivers
“across 8 life domains (occupation, financial, emotional, physical, sleep, social, planning and autonomy, and safety)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents included 239 patients with gMG (63%, aged 18–49 y; 69%, female) and 81 caregivers (58%, aged 18–49 y; 42% female).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 5 domains most impacted by gMG were occupational (mean domain score [SD]: 4.0 [1.2]), planning and autonomy (4.0 [1.1]), financial (3.9 [1.2]), physical (3.9 [1.1]), and sleep (3.9 [1.2]) for patients and financial (3.7 [1.2]), sleep (3.7 [1.1]), occupational (3.6 [1.2]), planning and autonomy (3.6 [1.1]), and safety (3.6 [1.1]) for caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eligible patients were aged ≥ 18 years currently living in the United States with a self-reported physician diagnosis of gMG regardless of antibody status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of psychological symptoms and health-related quality of life
“Sixty-seven publications were included in the SLR. Compared with the general population, patients with MG experienced worse HRQoL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, in general those with more severe symptoms and hospitalization days had worse depression and anxiety, and fatigue and sleep improved with disease remission and/or improvement. Scores were worse for females compared with males and where evaluated, HRQoL scores generally improved following treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Incremental annual costs of newly diagnosed gMG compared with matched controls: U.S. claims, 2017 to 2023
“Adults with newly diagnosed gMG were identified from Komodo Research data (January 1, 2017, to September 30, 2023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The gMG cohort (mean follow-up = 32.7 months) compared with the non-MG cohort (mean follow-up = 31.3 months) had 2.4, 1.6, and 1.9 times more inpatient days, emergency department visits, and outpatient visits annually, respectively (all P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean annual all-cause total health care costs in the gMG cohort were $43,872 higher than in the non-MG cohort ($58,341 vs $14,469; P < 0.001); 59.3% of the difference was driven by pharmacy costs (mostly immunoglobulin).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prediagnosis weakness and fatigue symptoms, exacerbation or crisis, and use of immunoglobulin were important factors significantly associated with high health care costs in the gMG cohort (all P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs associated with exacerbations and crises in newly diagnosed gMG: U.S. claims
“After re-weighting, patients with a clinical event had higher number of inpatient admissions [rate ratio (RR) = 6.02], emergency visits (RR = 1.91), and outpatient visits (RR = 1.58; all p < 0.05) in the 12 months post-index. Mean total healthcare costs were $70,792 higher among patients with a clinical event ($95,821 vs. $25,029, p < 0.001), driven by immunoglobulin and inpatient costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incremental costs and event-related costs in prevalent and incident gMG: U.S. claims, 2017 to 2023
“Analyses included 16,561 gMG patients (12,813 prevalent and 3748 incident) and 105,716 non-gMG controls. Among prevalent and incident gMG patients, respectively, MG exacerbation occurred during follow-up in 12.2 and 22.0% and myasthenic crisis in 6.0 and 12.4%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After weighting, gMG patients (median follow-up 696 days) experienced more frequent all-cause HCRU encounters and >4-fold higher healthcare costs ($5420 PPPM or ∼$65,000 per annum) versus non-gMG controls ($1298 PPPM or ∼$15,500 per annum).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among MG patients, those with MG exacerbation/myasthenic crisis, respectively, experienced means of 3.02/3.35 hospitalizations, 1.91/2.13 emergency department encounters, 12.70/13.39 skilled nursing facility encounters, and 67.86/75.52 outpatient encounters during follow-up; associated costs were $17,113/$18,640 PPPM (or ∼$205,000/$224,000 per annum).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incremental monthly costs and the effect of comorbidities and acute events: U.S. claims, 2017 to 2021
“The gMG and matched non-MG cohorts each contained 2,739 patients. Mean incremental healthcare costs associated with MG were $4,155 (gMG: $5,567; non-MG: $1,411), with differences driven by incremental inpatient costs of $2,166 (gMG: $2,617; non-MG: $452); all p < 0.001.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with gMG in cardiometabolic (n = 1,859), psychiatric (n = 1,308), and exacerbation/crisis (n = 419) subgroups, mean monthly healthcare costs were $6,660, $7,443, and $17,330, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
First-year costs after diagnosis by payer: U.S. commercial and Medicare claims, 2016 to 2021
“The final analytic cohort included 3,700 patients with MG and 37,000 controls. On average, patients were aged 54 years, with 60% being female. The difference-in-difference estimates of the total health care cost for MG diagnosis in commercial and Medicare patients were $25,799 and $4,927, respectively (P < 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs in newly diagnosed and previously diagnosed patients and around crisis events: U.S. claims, 2014 to 2019
“Mean HCRU and costs were higher for newly diagnosed patients compared with previously diagnosed patients (hospitalizations: 0.46 vs. 0.34; all-cause costs: $26,419.20 vs. $24,941.47; direct costs for gMG treatments: $9,890.37 vs. $9,186.47) and further increased for patients with exacerbation events (hospitalizations: 0.72; all-cause costs: $43,734.15; direct costs for gMG treatments: $21,550.02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients who experienced crisis events, HCRU and costs markedly increased during the 12 months immediately before the crisis event (hospitalizations: 1.35; all-cause costs: $49,236.68) compared with the 2 preceding years and increased further during the 12 months following the crisis index date (hospitalizations: 2.78; all-cause costs: $173,956.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs in patients treated with chronic IVIg or multiple nonsteroidal immunosuppressants
“Compared with the reference cohort (n = 2992), the MG crisis rate was approximately twice as high in both the chronic IVIg (n = 324) and multiple NSIST (n = 291) cohorts (p < 0.001); and the MG exacerbation rate was approximately four-fold higher in the chronic IVIg cohort (p < 0.001) and three-fold higher in the multiple NSIST cohort (p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median annual MG-related inflation-adjusted total healthcare costs were higher in the chronic IVIg ($81,900) and multiple NSIST ($30,300) cohorts than in the reference cohort ($2540).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs by glucocorticoid exposure: U.S. commercial claims
“Annual all-cause costs were >2x higher among patients with any GC use than those with no GC use ($76,381 vs $35,309). GC acute and chronic toxicities and costs tended to increase with increasing GC use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization trends: U.S. Nationwide Inpatient Sample and Medicare, 2010 to 2019
“Hospitalization rates for 19,715 unique adult patients and 56,822 admissions increased from 2010 to 2019 at an average annualized rate of 4.9% (MG noncrisis: 4.4%; MG crisis: 6.8%; all p < 0.001). Readmission rates were approximately 20% in each study year for both crisis and noncrisis hospitalizations; the in-hospital mortality rate averaged 1.8%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average LOS was stable over the study period, ranging from 11.3 to 13.1 days, but was consistently longer for MG crisis admissions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Range of direct and indirect costs across studies: systematic reviews
“Across studies, the mean per-patient annual direct medical cost of illness was estimated at between $760 and $28,780, and cost per hospitalization between $2550 and $164,730. The indirect cost of illness was estimated at $80 and $3550.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs varied considerably by patient characteristics, and drivers of the direct medical cost of illness included intravenous immunoglobulin and plasma exchange, myasthenic crisis, mechanical ventilatory support, and hospitalizations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“1374 records were identified initially, and 44 were included in the final review.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Direct costs include treatment and follow-up in the primary and specialist health care. They were estimated to €3 500–12 000 per MG patient per year in the Nordic countries, similar in other European countries, and higher in United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intangible costs include value of lost life-years and reduced quality of life, which are rarely assessed, but have been estimated to be half of the total societal MG costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment escalation and first-year MG-related costs in newly diagnosed adults: U.S. MarketScan claims, 2010 to 2018
“Patients aged ≥ 18 years at MG diagnosis were included from two US Merative™ MarketScan® databases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cohort included 4925 adults with newly diagnosed MG (1102 aged 18–49 and 3823 aged ≥ 50 at first MG diagnosis) from January 1, 2010 to December 31, 2018.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 71.5% (3521/4925) of patients had ≥ 1 MG treatment escalation; escalation with high-dose corticosteroids was the most common type (64.8% [18–49 group] and 58.5% [≥ 50 group]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Healthcare resource utilization (HCRU) and costs were highest in Year 1, with mean MG-related costs per patient between $24,982 (≥ 50 group) and $33,023 (18–49 group).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket and aggregate costs of eculizumab for myasthenia gravis: U.S. commercial and Medicare supplemental claims
“We used the Merative MarketScan commercial and Medicare supplemental databases to observe patients seen by a neurologist with neurologic diseases with newly FDA-approved medications from 2014 to 2021” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 2,687 unique individuals with ALS, 38 with ATTR, 69 with DMD, 884 with HD, 9,984 with MG, 441,099 with migraine, 4,723 with OH, 1,266 with TD, and 17 with SMA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eculizumab for MG was an extreme outlier, with OOP costs increasing by 4,099% ($413-$17,359) and aggregate OOP costs by 7,005% ($5,375-$381,894).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthcare resource utilization before and after rozanolixizumab initiation: U.S. Komodo claims, July 2023 to March 2025
“Patients were selected from de-identified claims data from the Komodo Healthcare Map® (July 2023–March 2025).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The main study included 719 patients. Patients with ≥ 365 days since rozanolixizumab initiation (n = 287) started a mean (standard deviation) 2.9 (1.8) treatment cycles in Year 1. Total MG-related HCRU incidence rates per 100 person-years were 88.0 during baseline and 82.9 during follow-up, and 86.2 versus 80.8 for outpatient, 25.6 versus 17.3 for inpatient, and 24.9 versus 14.0 for emergency room visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exacerbation rate and healthcare resource utilization by MG-ADL score: MGFA Global MG Patient Registry, United States, 2013 to 2022
“Participants were based in the USA, aged ≥ 18 years, had a self-reported MG diagnosis and complete MG-ADL data, and were enrolled between July 1, 2013 and September 30, 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 3416 patients (2092 [61.2%] females) were eligible; mean (standard deviation) age at diagnosis was 49.4 (17.4) years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For each additional point on the MG-ADL score, the rate of exacerbations increased by 13% (incidence rate ratio: 1.13; 95% confidence interval: 1.11–1.15; p < 0.001). At enrollment, 49.6% (n = 386/778) of patients who had one exacerbation had HCRU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Acute care utilization by race and ethnicity in the 2 years after diagnosis: U.S. Optum claims, 2010 to 2019
“A retrospective cohort study was conducted among adults (≥18 years) with newly diagnosed MG in the United States using Optum’s de-identified Market Clarity Data from January 1, 2010, to December 31, 2019.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with patients identifying as Caucasian, those identifying as African American had 37% higher odds of having an emergency department visit in year 1, and those identifying as Hispanic had 70% increase in odds of having a hospitalization event in year 2 post-diagnosis. Among other covariates, Medicaid usage, exacerbation at index, and number of outpatient visits were significantly associated with acute care utilization.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Generalized myasthenia gravis on families
Out-of-pocket costs and financial adjustments reported by U.S. patients and caregivers
“Eight hundred people with MG and 238 caregivers responding on behalf of a person with MG completed the survey.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“70% reported making financial adjustments or seeking financial assistance. Annual out-of-pocket costs (mean, $15,798; median, $7750) were primarily driven by medications, cost to receive a diagnosis, and healthcare insurance premiums. People receiving infusions paid significantly more across all care domains.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient and caregiver productivity losses by symptom severity: MyRealWorld MG
“In the MyRealWorld-MG study, 36.5% of MG patients reported taking sick leave within the last month and 11.4% reported stopping work (or retiring early) due to MG. Furthermore, 36.0% required caregiver support with 14.6% of caregivers reducing working hours and 13.4% stopping work.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with severe MG incurred 3.8 times more productivity losses compared to patients with mild disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual productivity losses per patient in the United States by MG-ADL category
Caregiver burden measured with the Zarit Burden Interview in five European countries
“A cross-sectional study design collected patient and caregiver data in Germany, Italy, Spain, the UK, and France.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers (N = 69) reported a mean ZBI-22 score of 24.3, with 40.6% reporting no burden, 47.8% mild-to-moderate burden, 8.7% moderate-to-severe burden, and 2.9% severe burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Informal caregivers of MG patients experience a substantial burden, impacting their physical, emotional, and financial well-being.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sick leave and need for caregiver help compared with the general population
“Taking sick leave in the past month was 2.6 times more frequent among people diagnosed with MG compared to the general population (34.4% vs. 13.2%) and four times more people diagnosed with MG reported needing help from a caregiver (34.8% vs. 8.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic concerns of U.S. adults with gMG facing social determinants of health barriers
“The survey was completed by 38 individuals living with gMG, the majority of whom were enrolled in public insurance and not employed. The most commonly reported major economic concerns were managing funds for emergency care (66%), loss of income (61%), and non-medical expenses (58%), highlighting the diversity of economic challenges.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Out-of-pocket cost of receiving a diagnosis reported by U.S. patients
Medicaid payment rates for acetylcholine receptor and MuSK antibody tests: Massachusetts, January 2024
Approaches to treatment
Current treatment options and standard of care
Acetylcholinesterase inhibitors
Pyridostigmine as initial symptomatic treatment: international consensus guidance
“Pyridostigmine should be part of the initial treatment in most patients with MG. Pyridostigmine dose should be adjusted as needed based on symptoms. The ability to discontinue pyridostigmine can be an indicator that the patient has met treatment goals and may guide the tapering of other therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Corticosteroids or IS therapy should be used in all patients with MG who have not met treatment goals after an adequate trial of pyridostigmine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pyridostigmine dosing, adverse effects, and second-line symptomatic agents: Nordic guidance
“Pyridostigmine represents the first‐line symptomatic treatment, while ambenonium and beta adrenergic agonists are second‐line options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pyridostigmine dosage is titrated individually, where 30–60 mg every 4–6 h is a typical adult dose” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a Dutch–Belgian cohort, 91% reported side effects from pyridostigmine, and one in four discontinued the treatment mainly due to side effects” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pyridostigmine in optimal dose should be given as a first‐line symptomatic treatment in most patients with MG. The optimal dose can vary according to activity needs and be adjusted by the patient accordingly. Terbutaline and salbutamol can be used as adjuvant symptomatic treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA-labeled indication and dosing: pyridostigmine
Corticosteroids
Corticosteroid use and tapering: international consensus guidance
“Once patients achieve treatment goals, the corticosteroid dose should be gradually tapered. In many patients, continuing a low dose of corticosteroids long-term can help to maintain the treatment goal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because corticosteroids may cause transient worsening of myasthenic weakness, it may be appropriate to wait several days for PLEX or IVIg to have a beneficial effect before starting corticosteroids” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Corticosteroid dosing and combination with a steroid-sparing agent: Nordic guidance
“Early high‐dose oral prednisone or prednisolone is recommended (0.75–1.00 mg/kg) in patients with moderate to severe generalized MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with mild to moderate generalized MG, steroids can be given at lower doses (0.25 mg/kg), followed by gradual escalation depending on the clinical response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A gradual increase of steroid dose from 5 to 10 mg daily over a few weeks is recommended to avoid an initial worsening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 75% of patients, steroids have an effect within 2–4 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to the high risk of long‐term adverse effects and to further improve muscle weakness, corticosteroids should be combined with another immunosuppressive drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Daily corticosteroid dosing as standard practice: British guideline update
Glucocorticoid exposure in US commercially insured adults with generalized myasthenia gravis
Nonsteroidal immunosuppressive agents
Indications for and choice of nonsteroidal immunosuppressive agents: international consensus guidance
“A nonsteroidal IS agent should be used alone when corticosteroids are contraindicated or refused. A nonsteroidal IS agent should be used initially in conjunction with corticosteroids when the risk of steroid side effects is high based on medical comorbidities. A nonsteroidal IS agent should be added to corticosteroids when: a. Steroid side effects, deemed significant by the patient or the treating physician, develop; b. Response to an adequate trial (table e-1) of corticosteroids is inadequate; or c. The corticosteroid dose cannot be reduced due to symptom relapse.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonsteroidal IS agents that can be used in MG include azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, and tacrolimus. The following factors should be considered in selecting among these agents: a. There is widespread variation in practice with respect to choice of IS agent since there is little literature comparing them. b. Expert consensus and some RCT evidence support the use of azathioprine as a first-line IS agent in MG. c. Evidence from RCTs supports the use of cyclosporine in MG, but potential serious adverse effects and drug interactions limit its use. d. Although available RCT evidence does not support the use of mycophenolate and tacrolimus in MG, both are widely used, and one or both are recommended in several national MG treatment guidelines” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For nonsteroidal IS agents, once treatment goals have been achieved and maintained for 6 months to 2 years, the IS dose should be tapered slowly to the minimal effective amount.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate as a steroid-sparing agent: 2020 consensus update
“An RCT enrolled 50 patients with AChR-Ab+ MG taking prednisone at a dose of ≥10 mg/d. 34 Patients were randomized 1:1 to MTX 20 mg/wk or placebo. There was no difference in the primary outcome measure, the area under the prednisone dose-time curve between months 4 and 12, and the mean 12-month change in QMG, MMT, MG-Quality of life, MG-ADL, and MGC was no different between treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although evidence from RCTs is lacking, oral MTX may be considered as a steroid-sparing agent in patients with generalized MG who have not tolerated or responded to steroid-sparing agents that are better supported by RCT data” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Azathioprine first choice and onset of effect: Nordic guidance
“These drugs have a delayed response of 1 to 6 months, and the full effect is sometimes reached after more than 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Nordic countries, azathioprine (2–3 mg/kg) is usually the first‐line treatment in both adults and children. Mycophenolate (1–2 g daily), methotrexate (20 mg/week), and tacrolimus (3 mg daily) are secondary alternatives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Azathioprine is recommended as the first‐choice non‐steroidal immunosuppressant drug. Mycophenolate, methotrexate, and tacrolimus are recommended as secondary immunosuppressants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Thymectomy
Thymectomy in nonthymomatous AChR antibody-positive disease: 2020 consensus update
“In nonthymomatous, generalized MG patients with AChR-Ab, aged 18–50 years, thymectomy should be considered early in the disease to improve clinical outcomes and to minimize immunotherapy requirements and the need for hospitalizations for disease exacerbations (median 9, range 2–9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thymectomy should be strongly considered in patients with AChR-Ab+ generalized MG if they fail to respond to an initial adequate trial of immunotherapy or have intolerable side effects from that therapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current evidence does not support an indication for thymectomy in patients with MuSK, low-density lipoprotein receptor–related protein 4, or agrin antibodies” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MGTX randomized trial: 3-year results
“A total of 126 patients underwent randomization between 2006 and 2012 at 36 sites. Patients who underwent thymectomy had a lower time-weighted average Quantitative Myasthenia Gravis score over a 3-year period than those who received prednisone alone (6.15 vs. 8.99, P<0.001); patients in the thymectomy group also had a lower average requirement for alternate-day prednisone (44 mg vs. 60 mg, P<0.001). Fewer patients in the thymectomy group than in the prednisone-only group required immunosuppression with azathioprine (17% vs. 48%, P<0.001) or were hospitalized for exacerbations (9% vs. 37%, P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thymectomy improved clinical outcomes over a 3-year period in patients with nonthymomatous myasthenia gravis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MGTX extension: 5-year results
“Of 111 subjects who completed the 3-year MGTX trial, 68 (61%) entered the extension study between September 1, 2009 and August 26, 2015 (33 prednisone alone; 35 prednisone plus thymectomy).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 5 years, patients randomised to thymectomy plus prednisone continued to demonstrate improved clinical status compared to patients in the prednisone alone group based on time-weighted average QMG (5.47±3.87 vs. 9.34±5.08; 95% CI for the difference 0.71–7.04; p=0.0007) and lower average alternate-day prednisone requirements (24 mg±21 mg vs. 48±29 mg; 95% CI for the difference 12–36 mg; p=0.0002). The proportion of patients requiring hospitalisation for MG exacerbation (6% vs. 30%; 95% CI for the difference 7.1–42.1%; p=0.0105) was lower in the thymectomy group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AAN practice advisory on thymectomy
“For patients with nonthymomatous AChR ab+ generalized MG, treatment with thymectomy plus prednisone is probably more effective than treatment with prednisone alone for increasing the chance of attaining minimal manifestation status (risk difference at 36 months, 20%; 95% confidence interval, 1.6%-37%; moderate confidence in the evidence).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Clinicians should discuss thymectomy treatment with patients with AChR ab+ generalized MG (Level B).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Timing of thymectomy by age: Nordic guidance
“In patients with non‐thymoma, generalized MG, AChR antibodies, and age below 50 years, thymectomy should be performed within 4 months from diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with non‐thymoma generalized MG, AChR antibodies, and age 50–65 years, early thymectomy should be considered if minimal manifestations are not reached, or the patient has substantial side effects from treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Minimally invasive techniques are preferred with fewer perioperative complications, shorter hospitalization time, and minimal scars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intravenous immunoglobulin and plasma exchange
Short-term and maintenance use: international consensus guidance
“PLEX and IVIg are appropriately used as short-term treatments in patients with MG with life-threatening signs such as respiratory insufficiency or dysphagia; in preparation for surgery in patients with significant bulbar dysfunction; when a rapid response to treatment is needed; when other treatments are insufficiently effective; and prior to beginning corticosteroids if deemed necessary to prevent or minimize exacerbations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IVIg and PLEX are probably equally effective in the treatment of severe generalized MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of IVIg as maintenance therapy can be considered for patients with refractory MG or for those in whom IS agents are relatively contraindicated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PLEX and IVIg are the mainstay of management in myasthenic crisis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Crisis treatment and maintenance immunoglobulin: Nordic guidance
“Plasma exchange and intravenous immunoglobulin are the primary treatments recommended for crisis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Immunoglobulins, given intravenously or subcutaneously, are rarely used as maintenance therapy. A recent study found no steroid‐sparing effect of intravenous immunoglobulin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Randomized trials of immunoglobulin in myasthenia gravis: 12 trials and 515 participants
“We included 12 RCTs (11 with usable data; 515 participants) conducted between 1997 and 2025 in Europe, North America, and Asia. All studies assessed IVIg; none assessed SCIg. Comparators included PLEX (six trials), placebo (five trials), and corticosteroids (one trial).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We found low‐certainty evidence that IVIg may improve symptoms and functional capacity in the medium term in people with MG, compared to placebo, though the effects did not reach commonly used thresholds for clinical significance and were based on sensitivity analyses. Based on moderate‐certainty evidence, IVIg probably also increases the incidence of headache. Based on very low to low‐certainty evidence, IVIg may be less beneficial than PLEX for short‐term improvement in symptoms and may prolong hospital stay, though we found no differences in adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement c5 inhibitors
Eculizumab in refractory AChR antibody-positive disease: 2020 consensus update
“In a phase III international multicenter RCT of 125 patients with refractory generalized nonthymomatous AChR-Ab+ MG (REGAIN), the primary outcome measure of change in the MG-ADL score from baseline to week 26, measured by worst-rank analysis of covariance, was not significantly different ( p = 0.0698) between eculizumab and placebo arms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eculizumab should be considered in the treatment of severe, refractory, AChR-Ab+ generalized MG (median 9, range 2–9). The role of eculizumab in the treatment of MG is likely to evolve over time. Until further data become available to allow comparisons of cost and efficacy with other treatments, eculizumab should be considered after trials of other immunotherapies have been unsuccessful in meeting treatment goals (median 9, range 5–9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement inhibitors and FcRn blockers as second-line treatments: Nordic guidance
“Several inhibitors of complement proteins have appeared within the last 5 years as a new treatment modality for refractory or difficult‐to‐treat MG patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment effect is seen within the first 2 weeks and maximal effect appears within the first 2 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to high drug costs, complement and FcRn inhibitors are recommended only for difficult‐to‐treat patients with severe MG not responding to standard immunosuppressive treatment. Complement and FcRn inhibitors act fast, have a proven effect with an acceptable safety profile, with a selective impact on the immune system. If costs permit and are acceptable, they should be recommended as alternative second‐line treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eculizumab: FDA-labeled indication, dosing, and pivotal trial
Eculizumab biosimilars: FDA-labeled indication
Ravulizumab: FDA-labeled indication, dosing, and pivotal trial
Zilucoplan: FDA-labeled indication, dosing, and pivotal trial
Target of approved complement inhibitors
“To date, all FDA-approved drugs in this category focus on targeting the C5 convertase enzyme.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Zilucoplan is a small macrocyclic peptide that not only binds to C5 to inhibit its cleavage, but also interferes with C5b binding to C6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eculizumab: REGAIN phase 3 trial in refractory AChR antibody-positive disease, 26 weeks
“Eligible patients were aged at least 18 years, with a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of 6 or more, Myasthenia Gravis Foundation of America (MGFA) class II-IV disease, vaccination against Neisseria meningitides, and previous treatment with at least two immunosuppressive therapies or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 months without symptom control.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between April 30, 2014, and Feb 19, 2016, we randomly assigned and treated 125 patients, 62 with eculizumab and 63 with placebo. The primary analysis showed no significant difference between eculizumab and placebo (least-squares mean rank 56·6 [SEM 4·5] vs 68·3 [4·5]; rank-based treatment difference -11·7, 95% CI -24·3 to 0·96; p=0·0698).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Myasthenia gravis exacerbations were reported by six (10%) patients in the eculizumab group and 15 (24%) in the placebo group. Six (10%) patients in the eculizumab group and 12 (19%) in the placebo group required rescue therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The use of a worst-rank analytical approach proved to be an important limitation of this study since the secondary and sensitivity analyses results were inconsistent with the primary endpoint result; further research into the role of complement is needed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ravulizumab: CHAMPION MG phase 3 trial, 26 weeks
“In this randomized, double-blind, placebo-controlled, multinational trial, we randomly assigned (1:1) patients with anti-AChR antibody-positive gMG to intravenous ravulizumab or placebo for 26 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 175 patients were enrolled. Ravulizumab significantly increased the magnitude of mean changes from baseline to week 26 versus placebo in MG-ADL (−3.1 vs. −1.4; P<0.001) and QMG (−2.8 vs. −0.8; P<0.001) total scores.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“QMG total scores improved by 5 points or more in a significantly greater proportion of ravulizumab-treated patients than of those receiving placebo (30.0% vs. 11.3%; P=0.005).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Zilucoplan: RAISE phase 3 trial, modified intention-to-treat population, 12 weeks
“Between Sept 17, 2019, and Sept 10, 2021, 239 patients were screened for the study, of whom 174 (73%) were eligible. 86 (49%) patients were randomly assigned to zilucoplan 0·3 mg/kg and 88 (51%) were assigned to placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients assigned to zilucoplan showed a greater reduction in MG-ADL score from baseline to week 12, compared with those assigned to placebo (least squares mean change -4·39 [95% CI -5·28 to -3·50] vs -2·30 [-3·17 to -1·43]; least squares mean difference -2·09 [-3·24 to -0·95]; p=0·0004).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TEAEs occurred in 66 (77%) patients in the zilucoplan group and in 62 (70%) patients in the placebo group. The most common TEAE was injection-site bruising (n=14 [16%] in the zilucoplan group and n=8 [9%] in the placebo group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Gefurulimab: FDA-labeled mechanism, pivotal trial responder rates, and adverse reactions
Gefurulimab: PREVAIL phase 3 trial, 26 weeks
“This randomized clinical trial, PREVAIL, was a phase 3, double-blind, placebo-controlled study conducted at 113 sites in 20 countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 405 patients screened, 145 were excluded; 260 met eligibility criteria and were randomized (gefurulimab, n = 131; placebo, n = 129); 249 patients completed the 26-week randomized controlled treatment period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Least-squares mean change from baseline at week 26 for MG-ADL and QMG total scores for gefurulimab vs placebo were −4.2 vs −2.6 (treatment difference, −1.6; 95% CI, −2.4 to −0.8; P < .001) and −4.5 vs −2.4 (treatment difference, −2.1; 95% CI, −3.1 to −1.1; P < .001), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of adverse events (AEs) was similar between groups. Most common treatment-emergent AEs with gefurulimab were injection site reactions, headache, back pain, and nasopharyngitis. No meningococcal infections were reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement C5 inhibitor initiation, monotherapy, and response assessment: German-Austrian expert recommendations
“Recommendation (consensus): Add‐on therapy with C5‐I should be considered for patients with (highly) active gMG (including therapy‐refractory disease) who are positive for AChR autoantibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation (consensus): The use of C5‐I as monotherapy should be considered only in exceptional cases, for example, when standard immunotherapies are ineffective, associated with intolerable AEs, or contraindicated, including in the context of chronic infection or malignancy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation (strong consensus): Treatment response should be assessed after 12 weeks of C5‐I therapy, as clinical response or non‐response can usually be determined by this time and used to guide further treatment planning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neonatal fc receptor blockers
Mechanism, onset, and comparative effect of FcRn blockers: Nordic guidance
“Monoclonal antibodies directed at the FcRn receptor's binding site for IgG block recycling and lead to a 60%–70% reduction in circulating IgG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment can be tailored according to the disease state; new treatment cycles can be administered with signs of symptom worsening or according to a fixed schedule.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The number of treatment responders and the magnitude of the treatment response for FcRn blockers and complement inhibitors seem to be similar. No prospective and controlled head‐to‐head studies have been undertaken.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efgartigimod intravenous: FDA-labeled indication, dosing, and pivotal trials
Efgartigimod alfa and hyaluronidase subcutaneous: FDA-labeled indication and dosing
Rozanolixizumab: FDA-labeled indication, dosing, and pivotal trial
Nipocalimab: FDA-labeled indication, dosing, and pivotal trial
Efgartigimod intravenous: ADAPT phase 3 trial, AChR antibody-positive modified intention-to-treat population, first treatment cycle
“The primary endpoint was proportion of acetylcholine receptor antibody-positive patients who were MG-ADL responders (≥2-point MG-ADL improvement sustained for ≥4 weeks) in the first treatment cycle.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between Sept 5, 2018, and Nov 26, 2019, 167 patients (84 in the efgartigimod group and 83 in the placebo group) were enrolled, randomly assigned, and treated. 129 (77%) were acetylcholine receptor antibody-positive. Of these patients, more of those in the efgartigimod group were MG-ADL responders (44 [68%] of 65) in cycle 1 than in the placebo group (19 [30%] of 64), with an odds ratio of 4·95 (95% CI 2·21-11·53, p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Four (5%) efgartigimod-treated patients and seven (8%) patients in the placebo group had a serious adverse event.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Efgartigimod alfa and hyaluronidase subcutaneous: ADAPT-SC noninferiority trial, total IgG reduction at week 4
“The ADAPT-SC primary endpoint was met. The LSM estimate of percentage change from baseline in total IgG level at week 4 was −66.4% for the efgartigimod PH20 SC arm vs −62.2% for the efgartigimod IV arm (Table 2), giving a LSM difference of −4.2% (95% CI, −7.73 to −0.66).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of AChR-Ab+ participants in the efgartigimod PH20 SC and efgartigimod IV arms demonstrated similar percentages of MG-ADL responders (efgartigimod PH20 SC: 71.1%; efgartigimod IV: 71.7%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rozanolixizumab: MycarinG phase 3 trial, intention-to-treat population, day 43
“Between June 3, 2019, and June 30, 2021, 300 patients were assessed for eligibility, of whom 200 were enrolled. 66 (33%) were randomly assigned to rozanolixizumab 7 mg/kg, 67 (34%) to rozanolixizumab 10 mg/kg, and 67 (34%) to placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Reductions in MG-ADL score from baseline to day 43 were greater in the rozanolixizumab 7 mg/kg group (least-squares mean change -3·37 [SE 0·49]) and in the rozanolixizumab 10 mg/kg group (-3·40 [0·49]) than with placebo (-0·78 [0·49]; for 7 mg/kg, least-squares mean difference -2·59 [95% CI -4·09 to -1·25], p<0·0001; for 10 mg/kg, -2·62 [-3·99 to -1·16], p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent TEAEs were headache (29 [45%] patients in the rozanolixizumab 7 mg/kg group, 26 [38%] in the rozanolixizumab 10 mg/kg group, and 13 [19%] in the placebo group), diarrhoea (16 [25%], 11 [16%], and nine [13%]), and pyrexia (eight [13%], 14 [20%], and one [1%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Nipocalimab: Vivacity-MG3 phase 3 trial, antibody-positive intention-to-treat population, weeks 22 to 24
“Between July 15, 2021, and Nov 17, 2023, 199 patients were enrolled, and 196 patients received study drug (98 in the nipocalimab group and 98 in the placebo group); of these, 153 (77 in the nipocalimab group and 76 in the placebo group) were antibody-positive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The least-squares mean change in MG-ADL score from baseline to weeks 22, 23, and 24 was -4·70 (SE 0·329) in the nipocalimab group versus -3·25 (0·335) in the placebo group (difference -1·45 [95% CI -2·38 to -0·52]; p=0·0024).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Serious adverse events were reported for nine (9%) of 98 patients in the nipocalimab group and 14 (14%) of 98 patients in the placebo group, three of which had a fatal outcome (nipocalimab: myasthenic crisis; placebo: cardiac arrest and myocardial infarction).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
FcRn inhibitor initiation, cycle timing, and IgG monitoring: German-Austrian expert recommendations
“Recommendation (strong consensus): Add‐on therapy with FcRn‐I should be considered for patients with (highly) active gMG (including therapy‐refractory disease) who are positive for AChR‐ and MuSK‐autoantibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation (strong consensus): Timing of a new FcRn‐I cycle should be individualised.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation (strong consensus): FcRn‐I therapy should be accompanied by monitoring of infections and IgG levels, particularly before initiation and, if needed, at the beginning and end of individual treatment cycles depending on the values obtained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
B-cell depleting antibodies
Rituximab in MuSK and refractory AChR antibody-positive disease: 2020 consensus update
“A phase II RCT of RTX (Beat-MG) enrolled 52 patients with generalized nonthymomatous AChR-Ab+ MG on a stable regimen of prednisone for 4 weeks or prednisone plus another IS agent for 6 months. 27 Two cycles of RTX 6 months apart were compared to placebo with the primary outcome being a steroid-sparing effect (≥75% reduction in mean daily prednisone requirements in the 4 weeks before week 52 compared with the 4-week period before randomization). The study was designed to assess futility (nonsuperiority). Preliminary results reported that the area under the curve for prednisone was not significantly different between RTX and placebo groups, with 60% on RTX and 56% on placebo achieving the primary outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rituximab should be considered as an early therapeutic option in patients with MuSK-Ab+ MG who have an unsatisfactory response to initial immunotherapy (median 9, range 4–9). The efficacy of RTX in refractory AChR-Ab+ MG is uncertain. It is an option if patients fail or do not tolerate other IS agents (median 8, range 4–9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rituximab as a first-line option in new-onset disease: Nordic guidance
“In RINOMAX, 47 Swedish patients with new‐onset generalized MG (96% AChR‐antibody MG) were randomized to receive 500 mg rituximab or placebo as an add‐on to the standard of care. [ 43 ] Minimal disease manifestations at 16 weeks, defined as a Quantitative Myasthenia Gravis (QMG) score of 4 or less with a prednisolone dose ≤10 mg and no rescue treatment, was the primary endpoint. This was met by 71% in the active arm and 29% in the placebo group ( p = 0.007).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rituximab should be considered a first‐line immunosuppressive drug in newly onset disease, as an alternative to steroids and azathioprine. Rituximab should be considered for treatment‐refractory symptoms, although evidence for its effectiveness is weaker than in newly onset disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Early rituximab: British guideline update
“Randomised controlled trial evidence now supports early use of rituximab (within 1 year of generalised disease onset), although the evidence is less robust, but still likely to be useful, in established treatment-refractory MG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Randomized trials of rituximab in myasthenia gravis: two trials and 99 participants
“We included two RCTs with a total of 99 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rituximab's effects on symptom severity and functional ability in the long‐term are uncertain. The evidence suggests that rituximab results in little to no difference in its steroid‐sparing effect; however, it probably results in a large reduction in relapse requiring rescue therapy over nine months, based on results from two studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inebilizumab: FDA-labeled indication, dosing, and pivotal trial
Inebilizumab: MINT phase 3 trial with glucocorticoid taper, week 26
“Glucocorticoid therapy was tapered, starting at week 4, to a target of 5 mg per day by week 24.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 238 participants underwent randomization (119 per group). Participants who received inebilizumab had a greater reduction in the MG-ADL score than those who received placebo (least-squares mean change, -4.2 vs. -2.2; adjusted difference, -1.9; 95% confidence interval [CI], -2.9 to -1.0; P<0.001) at week 26.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Participants who received inebilizumab had a greater reduction in the QMG score than those who received placebo (least-squares mean change, -4.8 vs. -2.3; adjusted difference, -2.5; 95% CI, -3.8 to -1.2; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Inebilizumab was not associated with a higher incidence of serious adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
- Refractory disease: Refractory MG has been defined as a post-intervention status unchanged or worse after corticosteroids and at least 2 other immunosuppressive agents used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning. An estimated 10% to 20% of patients continue to have long-standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses, and about 20,000 patients with generalized MG are estimated to be intolerant of or to have an inadequate response to conventional treatment.
- Incomplete response to targeted biologics: Upward of thirty percent of patients do not benefit from complement inhibition. No head-to-head prospective studies have compared the novel therapies; in one analysis, FcRn inhibitors carried greater odds of treatment-related adverse events than placebo (odds ratio 2.20 [1.52-3.38]), while C5 inhibitors and CD19+ B-cell depletion showed odds comparable to placebo.
- Glucocorticoid toxicity: Incident glucocorticoid toxicities occurred in 61.9% of patients with any glucocorticoid use and 52.3% of those without; common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection, and chronic toxicities included dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension. Toxicities and costs tended to increase with increasing glucocorticoid use.
- Infection risk and REMS: Eculizumab, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis, meningococcal vaccination is required at least 2 weeks before the first dose of eculizumab, and eculizumab and zilucoplan are available only through restricted REMS programs. One case of meningococcal meningitis occurred despite vaccination in the eculizumab open-label extension. In Study 1 of efgartigimod, urinary tract infections occurred in 10% of efgartigimod-treated and 5% of placebo-treated patients, and respiratory tract infections in 33% and 29%.
- Administration burden: Reported limitations include the need for meningococcal vaccination and regular intravenous or subcutaneous injections; eculizumab is infused intravenously over 35 minutes in adults, and the safety of starting rozanolixizumab cycles sooner than 63 days after the start of the previous cycle has not been established. Current targeted therapies generally require lifelong repeated administration and “rarely induce durable treatment-free remission”.
- Cost: In one cost-effectiveness analysis, eculizumab at an estimated annual cost of $653,100 had an incremental cost-effectiveness ratio of $5,210,000 per QALY/evLYG, and efgartigimod at a placeholder price of $418,400 had $2,076,000 per QALY/evLYG. Very high drug costs have limited access to complement and FcRn inhibitors in most countries. Annual all-cause costs were $76,381 among patients with any glucocorticoid use and $35,309 among those without.
Refractory disease despite conventional immunosuppression
“Definition of refractory MG. PIS3 is unchanged or worse after corticosteroids and at least 2 other IS agents, used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning, as defined by patient and physician.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incomplete response to targeted biologics
“There remain upward of thirty percent of patients who do not benefit from complement inhibition, which demonstrates the importance of other mechanisms of autoantibody action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is a pressing need for such advancements, especially considering the proliferation of multiple costly treatment options with substantial minorities of patients showing a poor response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoid toxicity and associated costs
“Incident GC toxicities were higher in patients with any GC use than those without (61.9% vs 52.3%). Common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection; chronic toxicities were dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Meningococcal infection risk, vaccination, and REMS with complement C5 inhibitors
“One case of meningococcal meningitis occurred, despite vaccination in the OLE and the patient was successfully treated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vaccination against Neisseria meningitidis (both meningococcal conjugate Men ACWY and serogroup B or MenB) is required at least 2 weeks before starting treatment with eculizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration burden: infusion schedules and repeated injections
Cost and cost-effectiveness of targeted biologics
“For eculizumab, with an estimated annual cost of $653,100, the incremental cost-effectiveness ratio was $5,210,000 per QALY/evLYG (Table 2). For analyses of efgartigimod, we used a placeholder price of $418,400, which is the midpoint of the potential price range cited by the manufacturer.11 At this estimated price, efgartigimod has an the incremental cost per QALY/evLYG of $2,076,000 (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The price for eculizumab is extremely high and is distinctive for the amount by which it exceeds the price needed to reach traditional cost-effectiveness thresholds in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Very high drug costs have limited the accessibility to treatment in most countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In common with complement inhibitors, the availability of FcRn blockers is limited by high drug costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No head-to-head trials and higher odds of treatment-related adverse events with FcRn inhibitors
“In the past decade, several novel therapies have shown promise in treating generalized myasthenia gravis (MG); however, no head-to-head prospective studies have compared their efficacy and safety.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients treated with FcRn inhibitors had greater odds of treatment-related adverse events (odds ratio 2.20 [1.52-3.38]) compared with the placebo group, while C5i and CD19+ BCDT showed odds comparable to placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lifelong repeated administration of targeted therapies
Place in treatment, anticipated use, and care setting
Summary
- Guideline positioning of targeted biologics: Guidance states that clinicians should seek to initiate available targeted therapies in patients with gMG who have active symptoms and for whom conventional therapy does not achieve symptom control within 6 to 12 months or results in excessive treatment-related burden, with use as initial treatment driven by clinician judgment. Complement and FcRn inhibitors are recommended as second- or third-line treatment in severe MG exacerbations and crisis, and their roles are being established especially in patients unresponsive to conventional therapy. Expert recommendations state that an interclass switch should be considered for inefficacy, intolerable side effects, or patient preferences regarding type and frequency of administration, and that a switch to IVIg interval therapy should be considered when targeted immunotherapies fail.
- Intended population and setting for Descartes-08: The phase 3 AURORA trial enrolls adults with acetylcholine receptor autoantibody-positive generalized MG and administers six once-weekly outpatient infusions without preconditioning chemotherapy. The company states that the current standard of care consists of chronic steroids and other immunosuppressants and that complement and FcRn inhibitors are typically administered continually, estimates that MG affects over 106,000 patients in the U.S., and describes Descartes-08 as the only CAR-T in autoimmune disease it is aware of that is designed for outpatient administration without preconditioning chemotherapy. The company states that conventional DNA cell therapies are administered under close monitoring in an inpatient setting. Investigators of an earlier Descartes-08 study reported the feasibility of preparing the cells for patients on immunosuppressive therapy, using them without lymphodepletion chemotherapy, and administering them in the outpatient setting with minimal post-infusion monitoring, and a later publication describes a “biologic-like approach that involves an initial leukapheresis”. An investigator quoted by the company described outpatient retreatment without lymphodepleting chemotherapy as a potential option for patients who have cycled through multiple therapies.
- Recommendations on cellular therapy: EBMT recommendations state that cellular therapy in autoimmune diseases should be performed within a clinical trial whenever possible, at expert centres with JACIE accreditation for immune effector cell administration, that the need for and dose of lymphodepletion are not established, and that repeated dosing of BCMA CAR-T has been efficacious in MG without lymphodepletion. A 2026 article on CAR-T therapy in autoimmune disease states that current neurological evidence is limited to small early-phase studies and case reports, with one placebo-controlled trial (generalised MG), and that CAR-T therapy should be considered experimental and delivered in specialised centres.
- Other CAR-T approaches in MG: In a study of anti-BCMA/CD19 bispecific CAR-T cells given as a single infusion after fludarabine and cyclophosphamide lymphodepletion, 18 participants were enrolled; grade 1 cytokine release syndrome occurred in 39%, and among 17 who completed follow-up, MG-ADL improved by −8.6 (95% CI −10.2 to −7.0) and QMG by −15.4 (−17.6 to −13.2) by day 180, and 14 (82%) achieved minimal manifestations. Three patients with treatment-resistant MG treated with anti-CD19 CAR-T cells (KYV-101) after cyclophosphamide and fludarabine lymphodepletion achieved sustained remission for at least 19 months, and BCMA-directed CAR-T cells in two patients (one AChR-IgG, one MuSK-IgG) produced clinical improvement over 18 months. KYV-101 is being compared with standard-of-care immunosuppressive therapy in the phase 2/3 KYSA-6 study, and CABA-201 is being evaluated with cyclophosphamide and fludarabine and, at escalating doses, without that preconditioning.
- REMS change for approved CAR-T therapies: The FDA eliminated the REMS for currently approved BCMA- and CD19-directed autologous CAR T cell immunotherapies, removing the requirements for specially certified dispensing sites with on-site, immediate access to tocilizumab. Labeling now calls for monitoring for at least two weeks, including daily monitoring for at least one week, remaining near a healthcare facility for at least two weeks, and avoiding driving for two weeks. In 58 patients with myeloma, lymphoma, or acute lymphoblastic leukemia who received CAR T-cell infusion as outpatients and were seen daily for the first 7 to 10 days, 17 (41%), 16 (38%), and 9 (21%) were admitted between days 0 to 3, 4 to 7, and 8 to 30.
Company statement of unmet need with chronic immunosuppression and continually administered biologics
Company estimate of the U.S. myasthenia gravis population and market opportunity
Positioning as an outpatient CAR-T without preconditioning chemotherapy
Care setting compared with conventional DNA-based CAR-T cell therapy
“This study demonstrated the feasibility of preparing autologous RNA CAR T-cells (rCAR-T) for patients on immunosuppressive therapy, of using the cells without lymphodepletion chemotherapy, and of administering rCAR-T in the outpatient setting with minimal post-infusion monitoring due to the notable safety profile of the product.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While DNA-based CAR T-cell therapies are also moving to the outpatient setting, they still require close post-infusion monitoring with daily clinic visits as well as reservation of hospital beds in case severe toxicities develop.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Investigator statement on use after multiple prior therapies
Guideline positioning of complement and FcRn therapies
“several clinical trials have been published for newer targeted therapies in MG, predominantly those that inhibit the complement and neonatal Fc gamma receptor pathways, the roles of which are being slowly established especially in patients unresponsive to conventional therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Targeted therapies after 6 to 12 months of conventional therapy without symptom control: 2026 international consensus
“Clinicians should seek to initiate available targeted therapies* in patients with gMG who have active symptoms and for whom conventional therapy† does not achieve symptom control within 6–12 months or results in excessive treatment-related burden. Use of available targeted therapies as initial treatment (together with standard therapy where indicated) should be driven by clinician judgment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinicians should refer a patient with MG to (or comanage with) a specialist with expertise in MG management if there is no sustained clinical improvement within 3–6 months of treatment initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switching after inadequate response to targeted therapies: German-Austrian expert recommendations
“Recommendation (consensus): An interclass switch should be considered if therapy is ineffective at the appropriate dosage and duration, if intolerable side effects occur, or for patient preferences regarding type and frequency of administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation (strong consensus): A switch to IVIg interval therapy should be considered in cases where targeted immunotherapies fail to provide adequate clinical efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation (strong consensus): Patients who are clinically stable on IVIg or SCIg interval therapy without intolerable side effects should not be switched to C5‐I or FcRn‐I.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cellular therapy for severe refractory autoimmune disease within clinical trials at accredited centers: EBMT recommendations
“Whenever possible, CT in ADs should be performed in the context of a clinical trial with well-defined end points and eligibility criteria in accordance with GCPs and appropriate regulatory requirements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Such expert centres should have a JACIE accreditation for Immune Effector Cells (IEC) administration and established multidisciplinary team meetings and/or similar processes for CT as for HCT, involving AD specialists and haematologists working in tandem in the same place to support thorough assessment, treatment and follow-up of these high-risk fragile patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lymphodepletion requirement for CAR T-cell therapy in autoimmune disease not established: EBMT recommendations
“Of note, repeated dosing of BCMA CART has been efficacious in MG without LD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If and at what dose LD is needed for effective CART in AD is currently not established. As such, LD follows oncological guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CAR T-cell therapy in autoimmune neurological disease: experimental status, specialized centers, and complications
“Possible complications from CAR-T cells (box 1) are extensive and limit the use of these therapies to patients with ‘severe’ or ‘refractory’ autoimmune disease that is not otherwise responsive to existing treatment paradigms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current neurological evidence is limited to small early-phase studies and case reports, with only one placebo-controlled trial (generalised myasthenia gravis).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At present, CAR-T therapy should be considered experimental and delivered in specialised centres, pending longer term safety and durability data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BCMA/CD19 bispecific CAR T-cell therapy after fludarabine and cyclophosphamide lymphodepletion: single-arm phase 1 trial, 18 participants with refractory gMG
“Participants received lymphodepleting chemotherapy with fludarabine (30 mg/m2/day) and cyclophosphamide (300 mg/m2/day) for three consecutive days (days −5 to −3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Between May 3, 2023, and June 19, 2024, 18 patients were enrolled and received apheresis and a single CAR T cell infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The anti-BCMA/CD19 bispecific CAR T cells were generally safe, with no dose-limiting toxicities, no immune effector cell-associated neurotoxicity syndrome, and only grade 1 cytokine release syndrome (39% of patients). The most common grade 3 or worse adverse events within 28 days were hematological toxicities, including three leukopenia, three neutropenia, one anaemia, and one thrombocytopenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“17 participants completed follow-up. Clinical improvements by day 180 were −8.6 (95% CI −10.2 to −7.0) for MG-ADL score and −15.4 (−17.6 to −13.2) for QMG score. 14 participants (82%) achieved minimal manifestations, 15 (88%) stopped glucocorticoids, all stopped non-steroidal immunosuppressants, and eight (47%) had anti-acetylcholine receptor antibody negative seroconversion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CD19 CAR T-cell therapy after lymphodepletion: case series of 3 participants with refractory AChR antibody-positive MG
“We report on three patients with severe, treatment-resistant MG, including one patient with concomitant rheumatoid arthritis, treated with autologous, fully human anti-CD19 CAR T cells. All three patients achieve rapid, sustained clinical MG remission for at least 19 months, allowing discontinuation of MG-specific immunotherapies and substantial improvement in clinical and functional outcomes despite persistent detectable anti-AChR autoantibody titers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A second-generation investigational CAR T cell product (KYV-101, Kyverna Therapeutics) was used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Instead, it may at least partially be attributed to the effects of lymphodepletion (cyclophosphamide and fludarabine), which from approximately day −6 before CAR T cell infusion markedly reduces circulating immune effector cells capable of mediating antibody-dependent inflammation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BCMA CAR T-cell therapy after lymphodepletion: 2 participants with refractory AChR or MuSK antibody-positive MG
“We reported here chimeric antigen receptor (CAR) T cells targeting BCMA in two patients with highly relapsed and refractory myasthenia gravis (one with AChR-IgG, and one with MuSk-IgG). Both patients exhibited favorable safety profiles and persistent clinical improvements over 18 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants stopped all immunosuppressants and steroid one to three days before treatment initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CD19 CAR T-cell therapy in concomitant MG and Lambert-Eaton myasthenic syndrome: 2 participants
“Two women diagnosed with concomitant MG/LEMS experienced severe, increasing disease activity despite multiple immunotherapies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Within 2 months, both patients returned to everyday life, from wheelchair dependency to bicycling and mountain hiking, and remain stable at 6 and 4 months post-CAR T cell infusion, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ongoing CD19 CAR T-cell trials in gMG with and without lymphodepletion: KYSA-6 and RESET-MG
FDA elimination of REMS for approved autologous CAR T-cell therapies, June 2025
Outpatient administration of commercial CAR T-cell therapy in hematologic malignancies: 58 participants, 2022 to 2023
“Patients were seen daily in the cancer center day hospital for the first 7 to 10 days and then twice weekly through day 30.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty-eight patients received outpatient CAR T-cell infusion (33 myeloma, 24 lymphoma, and 1 acute lymphoblastic leukemia). Of these, 17 (41%), 16 (38%), and 9 patients (21%) were admitted between days 0 to 3, 4 to 7, and 8 to 30 after CAR T-cell infusion, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hospitalization was prevented in 15 of 35 patients who received tocilizumab for CRS as an outpatient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of treatment effect
Descartes-08: AChR antibody-positive subgroup, MGC response at month 3, mITT population (phase 2b)
“Similar results were observed for the participants comprising the AChR autoantibody-positive population, with significantly more MGC responders in the Descartes-08 group than in the placebo group (63.6% versus 12.5%, P = 0.025815; Extended Data Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (s.d.) change from baseline in the MGC score at month 3 for those who were AChR autoantibody-positive was −5.0 (5.62) for the Descartes-08 group and 0.1 (4.85) for those treated with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Minimum improvements in MGC and MG-ADL scores were higher for the Descartes-08 group than the placebo group at month 3 (Fig. 3), with 81.8% versus 37.5% of participants achieving a minimum of a 3-point improvement in the MGC score and 63.6% versus 25.0% of participants achieving a minimum of a 3-point reduction in the MG-ADL score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: AChR antibody-positive subgroup, MG-ADL change at month 3 and through month 12 (phase 2b)
“There was a significant and clinically meaningful reduction in the mean (s.d.) MG-ADL score at month 3 for the Descartes-08 group compared to the placebo group (−3.4 (2.84) versus 0.6 (2.93), P = 0.0409) (Extended Data Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This reduction in the MG-ADL score was maintained up to month 12 for those in the Descartes-08 group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: AChR antibody status as a marker of response (phase 2b)
“Similar trends in MGC response were observed between the overall cohort and the AChR autoantibody-positive population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Together, these results confirm that, while anti-AChR antibody status is useful in classifying disease, its relevance as a marker to track progression or response to treatment is limited” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In line with this limitation, anti-AChR antibody titer did not correlate with change in clinical disease, as measured by the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale (n = 21) (Fig. 3l and Extended Data Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: biologic-naive versus biologic-exposed participants, post hoc analysis, mITT population (phase 2b)
“A post hoc analysis was conducted to evaluate the magnitude of response to Descartes-08 in participants who were biologic-naive and those with prior biologic exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants with no prior exposure to complement inhibitors, FcRn inhibitors or CD19/CD20-targeting monoclonal antibodies (biologic-naive) demonstrated an improved response to Descartes-08 compared to those with prior biologic exposure, with 55.6% (n = 5/9) of participants achieving MSE by month 6, which was maintained through month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, the biologic-naive group had a greater proportion of MGC responders at month 3 compared to the group with prior biologic exposure (88.9% versus 33.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were also notable reductions in MG severity scores from baseline to month 3 for the biologic-naive group versus those with prior biologic exposure (mean (s.d.) score: MGC −7.7 (5.24) versus 1.0 (6.96); MG-ADL −5.2 (3.27) versus −2.5 (3.08); QMG −5.0 (3.84) versus −2.2 (4.92)), with scores further improved by month 12 (MGC −11.0 (4.0), MG-ADL −7.1 (1.9), QMG −9.4 (2.6)) (Extended Data Table 5 and Extended Data Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, 100.0% of biologic-naive participants maintained at least a clinically meaningful response at month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Biologic-exposed participants were non-responders to prior FcRn or complement inhibitor treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among biologic-naive patients, 55.60% achieved MSE by month 6, which was maintained through month 12 without additional treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: authors' interpretation of the biologic-exposure difference (phase 2b)
“There was a notable difference in response between participants who had prior treatment with—and poor response to—complement and FcRn inhibitors and those who were biologic-naive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This may represent a true difference in biology due to a yet-to-be-determined mechanism, an artifact of a small sample size or a reflection of more treatment-refractory disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, it is notable that, even in the cohort of patients who were nonresponders to biologics, a proportion achieved a clinically meaningful improvement in the MGC score after Descartes-08, in contrast to those who were randomized to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: biologic-naive participants with follow-up beyond month 3 (7 participants), company release, April 2025
Descartes-08: early-onset versus late-onset disease, prespecified analysis, mITT population (phase 2b)
“In a prespecified analysis stratifying participants by disease onset, 80.0% (n = 4/5) of those treated with Descartes-08 who had early-onset MG, defined as the development of symptoms before the age of 50 years, were MGC responders at month 3, compared to 20.0% (n = 1/5) in the placebo group (Extended Data Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reductions in MG severity were generally consistent between participants with early-onset MG and those with late-onset MG who were treated with Descartes-08.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: triple seronegative participants and the placebo response (phase 2b)
“The most pronounced improvements in MG severity scales in the placebo group—including one case of MSE—were observed in participants with triple seronegative MG, consistent with larger placebo-controlled studies that included this cohort of patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: postinfusion fever and response, mITT population (phase 2b)
“There were no notable differences in demographics or disease characteristics among participants randomized to Descartes-08 who developed a fever.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, those who developed a fever may have been more likely to respond and experience more pronounced symptom improvement, as measured by the MG-ADL score, than those who did not (Extended Data Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: cell dose and MGC response, post hoc analysis (phase 2b)
“A second post hoc analysis was conducted to assess cell dose infusion and MGC response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the mean cell dose per infusion was similar among those treated with Descartes-08, irrespective of whether they achieved a response or not (Extended Data Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descartes-08: response across MG types and severity, phase 1b/2a long-term follow-up
MuSK antibody-positive disease: response to conventional therapies
“Many patients with MuSK-MG respond poorly to ChEIs, and conventional pyridostigmine doses frequently induce side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with MuSK-MG appear to respond well to corticosteroids and to many steroid-sparing IS agents. They tend to remain dependent on prednisone despite concomitant treatment with steroid-sparing agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MuSK-MG responds well to PLEX, while IVIg seems to be less effective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MuSK antibody-positive disease: complement independence and thymectomy
“The observation of predominant IgG4 antibodies in patients with MuSK MG is indicative of immune response that corresponds with the IgG4 autoimmune diseases ( 9 ) and the antiinflammatory properties of the IgG4 that include the inability to activate complement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The thymus is normal ( 116 ), and thymectomy does not benefit patients with MuSK with MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rituximab response by antibody status
“A retrospective combined analysis of previously published case reports of 169 patients between January 2000 and August 2015 reported that 72% of MuSK-Ab + MG and 30% of AChR-Ab+ MG patients treated with RTX achieved MM status or better.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Seronegative disease: efgartigimod in anti-AChR antibody-negative adults
Antibody subgroups enrolled in FcRn blocker trials
Potential confounding of network meta-analysis treatment effects by age and sex
“Sensitivity analyses detected potential confounding of treatment effects by age and sex.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our findings also highlight how differences between trial populations may confound the interpretation of study outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Delayed response to C5 inhibition in therapy-refractory patients: German-Austrian expert guidance
“A clinical response is generally observed within the first 4 weeks after treatment initiation. In patients who do not achieve clinically meaningful improvement within 12 weeks, the decision to continue treatment or switch to an alternative therapy should be individualised [15, 17, 18, 20], as long‐term observational data from non‐placebo‐controlled studies suggest that delayed responses may occur, particularly in therapy‐refractory gMG patients treated with eculizumab or ravulizumab for several months or longer [39, 40].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
Treatment goal of minimal manifestation status: international consensus guidance
“Goals for the treatment of MG. MGFA Task Force Post-Intervention Status (PIS) classification Minimal Manifestation Status (MMS) or better,3 with no more than grade 1 Common Terminology Criteria for Adverse Events (CTCAE) medication side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal symptom expression as a patient-reported treatment goal
“‘Minimal symptom expression’ was defined as MG-ADL total score of 0–1 or MG-QOL15 total score of 0–3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MSE using the MG‐ADL shows promise in helping to determine success of treatment and may be the aspirational goal of MG treatment for the future once validated, particularly given the evolving treatment landscape in MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MSE, as a patient‐centric endpoint, can be used alongside clinician‐assessed measures and safety measures to support an integrated treatment goal that encompasses both efficacy and tolerability for the treatment of gMG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Steroid-sparing strategy and tapering
“Tapering of IS drugs is associated with risk of relapse, which may necessitate upward adjustments in dose. The risk of relapse is higher in patients who are symptomatic, or after rapid taper. d. It is usually necessary to maintain some immunosuppression for many years, sometimes for life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with generalized MG should be given a non‐steroid immunosuppressant to achieve a better clinical response and enable steroid dose reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tapering of corticosteroids, and non‐steroidal immunosuppressants, should be considered after 1–2 years in patients in stable remission or with minimal symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring for adverse effects of immunosuppression
“Patients must be monitored for potential adverse effects and complications from IS drugs. Changing to an alternative IS agent should be considered if adverse effects and complications are medically significant or create undue hardship for the patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients on steroids should be monitored for blood pressure, body weight, bone mineral density, blood glucose levels, sleep, and mood problems.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to spontaneous disease fluctuations, comorbidities, and changes in life conditions, regular long‐term specialized follow‐up is needed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring disease activity with MG-ADL and QMG
“The QMG takes up to 25 min to complete and requires technician training, a hand‐held dynamometer, a spirometer, and a stopwatch.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MG‐ADL is easy to administer, requires no additional training, is quick to complete (<10 min), and can be used in routine clinical practice or in clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 2‐point change seemed to provide the best balance between sensitivity (77%) and specificity (82%); thus, this analysis revealed that a 2‐point improvement in MG‐ADL score best indicated clinical improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physical training and shared goal setting: Nordic guidance
“Adapted physical training is recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients and doctors should together define ambitious treatment goals” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring for CRS, ICANS, and hematotoxicity after CAR T-cell therapy in autoimmune disease: EBMT recommendations
Hospitalization, distance to the treating center, and caregiver presence after CAR T-cell therapy: EBMT recommendations
“For hospitalization and distance to the accredited treating center, we refer to current EBMT guidelines for CT and ideally up to 14 days for AD patients without severe reactions. Patients should be located within 60 min of the center with the continuous presence of a caregiver educated to identify the potential complications maintained for a year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Daily CRS and ICANS monitoring and myelotoxicity surveillance: CD19 CAR T-cell case series in MG
“Patients were monitored daily for the development of CRS and immune effector cell–associated neurotoxicity syndrome (ICANS) during the first 10 days following anti-CD19 CAR T cell infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Myelotoxicity was defined as grade III or IV neutropenia or leukocytopenia persisting for more than 28 days and was monitored prospectively using regular laboratory assessments, performed several times per week during the first 30 days, approximately biweekly between days 30 and 90, and at longer intervals thereafter.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term observation revealed an episode of pneumonia in patient MG3, associated with B cell aplasia and hypogammaglobulinemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neutropenia, infection, and hypogammaglobulinemia management after lymphodepletion and CAR T-cell infusion: phase 1 trial in refractory gMG
“For neutrophil deficiency (absolute neutrophil count less than 1.0 × 109/L), granulocyte colony-stimulating factor and prophylactic antibiotics (mostly sulfamethoxazole and cephalosporins) were given.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For those with severe infections or hypogammaglobulinemia (IgG less than 4 g/L), 0.4–0.6 g/kg of intravenous immunoglobulin was administered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antimicrobial prophylaxis after CAR T-cell therapy: EBMT recommendations
“The risk of infection depends on the AD and degree of immunosuppression, and management should be carefully discussed upfront by a multidisciplinary team meeting (disease specialist, infection-disease specialist, hematologists and CART experts). A follow-up of potential infectious complications should be considered mandatory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sufficiently long anti-viral and antibacterial prophylaxis should be maintained according to patient individual risk and in line with institutional guidelines and current EBMT guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vaccination before and after CAR T-cell therapy: EBMT recommendations
“Vaccinations status should be assessed and updated before LD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vaccination after CART therapy is effective and risk consideration should guide the decision to vaccinate before the procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Live vaccines are contraindicated in AD patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vaccination before immunosuppressive therapy and before complement inhibitors: 2026 international consensus
“Clinicians should refer patients with MG to their primary care clinician or appropriate specialty (e.g., infectious disease) to complete immunization schedules, per local/national/World Health Organization guidelines and per local prescribing information for MG therapies as part of immunosuppressive therapy planning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinicians should refer patients with gMG for whom complement inhibitor therapies may be a future consideration to their primary care clinician or appropriate specialist to complete meningococcal vaccination and other treatment-specific vaccination, per local/national/World Health Organization guidelines and per local drug prescribing information.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Leukapheresis: T-cell counts, venous access, and immunosuppressant washout: EBMT recommendations
“To achieve a good product, drug-specific washout periods before leukapheresis have to be considered to optimize T cell fitness as listed in Table 5. Usual recommendations for a successful CART production advice for 200/mcl CD3+ T cell counts, but CD3+ T cell counts >50/mcl can be sufficient. Secure venous access has to be guaranteed in ADs, when planning leukapheresis and lymphodepleting conditioning (LD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Washout of MG-relevant immunotherapies before leukapheresis: EBMT recommendations
| Therapy | Recommendation in autoimmune disease |
|---|---|
| Steroids | “May be administered at dosages ≤10 mg/day prednisone (or equivalent), by 7 days before leukapheresis and before LD;”View highlighted excerpt for this quote |
| Mycophenolate mofetil, azathioprine, calcineurin inhibitors, mTOR inhibitors, and JAK inhibitors | “Discontinued at least 2 weeks before leukapheresis”View highlighted excerpt for this quote |
| Cyclophosphamide and methotrexate | “Discontinued at least 3 weeks before leukapheresis”View highlighted excerpt for this quote |
| Belimumab and B cell targeting antibodies (e.g. anti CD20) | “Discontinued at least 1 week before leukapheresis”View highlighted excerpt for this quote |
Timing of immunosuppressants around apheresis and lymphodepletion, and pre-lymphodepletion assessment of pulmonary reserve and bulbar function in MG
“EULAR–EBMT guidance allows low‐dose prednisone up to 7.5 mg 1 day prior to apheresis but advises tapering cell‐cycle blockers 4 weeks before lymphodepletion so that transduced T‐cells expand without pharmacologic brakes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Trial registries for autoimmune cellular therapies therefore recommend a meticulous pre‐diagnostic evaluation that captures comorbid infection, pulmonary reserve and bulbar function before lymphodepletion is even considered” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Application of the Immune Effector Cell‐Associated Encephalopathy (ICE) score beside continuous EEG was able to detect subclinical seizures in almost half of the patients whose formal ICANS grade had remained 0–1, suggesting that conventional grading alone is insufficient once neuromuscular weakness complicates the examination” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prolonged B-cell aplasia, hypogammaglobulinemia, and infections after CAR T-cell therapy
“A frequent long‐term consequence of anti‐CD19 CAR T‐cell therapy is prolonged B cell aplasia, persisting for years in up to 38% of patients and often resulting in hypogammaglobulinemia and increased infection risk requiring immunoglobulin replacement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Severe infections are frequent in the early period following CAR-T reinfusion, warranting antimicrobial prophylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hypogammaglobulinaemia is typically prolonged and may necessitate treatment of supplemental Immunoglobulin Replacement Therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Frequency of CRS, ICANS, hypogammaglobulinemia, cytopenias, and infection after CAR-based therapy in autoimmune disease: meta-analysis of 56 studies
“Of 3367 records screened, 56 studies met the inclusion criteria (15 eligible for meta-analysis; 41 synthesized qualitatively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across all AIDs, CRS of any grade occurred in 0·63, but grade ≥ 3 CRS and any grade of ICANS were negligible (both 0·00). Hypogammaglobulinaemia of any grade occurred in 0·47, while grade ≥ 3 events were rare. Cytopenias were common: neutropenia and anemia of any grade were most frequent. Severe cytopenias occurred in ≤0·3. Infection within 3 months occurred in 0·29.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Regular assessment of symptom burden, treatment burden, and quality of life; shared decision making: 2026 international consensus
“Clinicians should regularly assess a patient with MG at all disease stages for symptom burden, treatment burden, and quality of life, using the same measures to build an ongoing, overall picture of the disease and its impact.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinicians should engage patients with MG and their family/caregivers, as appropriate, to play an active role in shared decision making, so that patients' personal goals, values, and preferences are considered when discussing treatment plans.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients receiving glucocorticoids, clinicians should aim to reduce the glucocorticoid dose to prednisone equivalent ≤10 mg/d and optimally to ≤5 mg/d, using alternative agents as necessary, and monitor patients closely for MG worsening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
IgG monitoring under FcRn inhibitors and rituximab: German-Austrian expert guidance
“Drug‐specific safety parameters must be assessed before initiation and at every switch of immunotherapy. These include monitoring of IgG levels under FcRn‐I and RTX therapy (especially when used in combination).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Living consensus recommendations on CAR T-cell therapy for autoimmune diseases: 2026 EBMT, ISCT, and JACIE update
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary
- Clinically meaningful change: A 2-point improvement in the MG-ADL best predicted clinical improvement (correlation with physician impression of change r = 0.70), and anchor-based and distribution-based minimal clinically important difference cut-offs for the QMG were below a change of 3.0.
- Treatment goals: Guidance states that the ongoing goal is to achieve and sustain minimal symptoms and treatment-related adverse events with a patient-acceptable quality of life, and to reassess treatment when these cannot be sustained. A consensus definition of adequately controlled gMG requires an MGFA post-intervention status of clinical stable remission, pharmacologic remission, or minimal manifestations stable for a year, an MG-ADL score of 2 or less, no exacerbation in the last year requiring a change in immunosuppressive or rescue therapy, and no or mild adverse events to therapy.
- Effect sizes of targeted therapies: An analysis of 27 placebo-controlled randomized trials (placebo n = 1,086; treatment n = 1,232) estimated QMG reductions beyond placebo and standard of care of -3.63 (95% credible interval -4.43 to -2.77) points for FcRn inhibitors, -2.59 (-3.92 to -1.28) for C5 complement inhibitors, and -2.50 (-5.11 to 0.12) for CD19+ B-cell depletion, and MG-ADL effects of -1.93 (-2.21 to -1.65), -1.84 (-2.48 to -1.19), and -1.91 (-2.97 to -0.84); meaningful differences between classes were not observed. In an Argenx-funded study, intravenous efgartigimod had the lowest number needed to treat versus placebo for 3-point and 5-point QMG reductions and a 5-point MG-ADL reduction, rozanolixizumab had the lowest for a 3-point MG-ADL reduction, and the number needed to harm was similar across treatments. With eculizumab, minimal symptom expression on the MG-ADL was reached by 21.4% of patients versus 1.7% with placebo at REGAIN week 26, and by 22.9% and 27.8% of the eculizumab/eculizumab and placebo/eculizumab groups at extension week 130.
- Company expectations for Descartes-08: The company states that Descartes-08 is being developed with the goal of providing “sustained clinical benefit following a finite course of treatment”, that sustained benefits were observed through 12 months in the phase 2b trial, and that it believes a single course has the potential to transform the MG treatment paradigm. The company states that its cell therapies are designed to be dosed repeatedly like conventional drugs, in an outpatient setting and without pre-treatment chemotherapy, that retreatment is possible if symptoms return, and that achievement of minimal symptom expression over time remains a key treatment goal for physicians.
Company statement of sustained benefit after a finite course without chronic dosing
Retreatment if symptoms recur
Treatment goal named in company materials: minimal symptom expression
Ongoing treatment goal: minimal symptoms and treatment-related adverse events, 2026 international consensus
“The ongoing treatment goal in MG is to work toward, achieve, and sustain minimal symptoms and treatment-related adverse events, with a patient-acceptable quality of life (using validated measures).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with MG, if minimal symptoms, minimal treatment-related adverse events, and patient-acceptable quality of life cannot be sustained, clinicians should reassess treatment and make changes to achieve treatment goals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal clinically important difference of the MG-ADL: 2-point improvement
“Correlation of the delta MG-ADL score and physician impression of change between the visits was strong (r = 0.70, P < 0.0001). A 2-point improvement in the MG-ADL best predicted clinical improvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A 2-point improvement in the MG-ADL indicates clinical improvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Minimal clinically important difference of the QMG: anchor-based and distribution-based estimates
“One anchor-based and 3 distribution-based techniques were used to identify quantitative myasthenia gravis score (QMGS), repetitive nerve stimulation (RNS), and single-fiber electromyography (SFEMG) MCID cut-offs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MCID cut-offs were below a QMGS change of 3.0.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Minimal symptom expression attained with eculizumab: REGAIN week 26 and open-label extension week 130
“At REGAIN week 26, more eculizumab-treated patients achieved ‘minimal symptom expression’ versus placebo [MG-ADL: 21.4% vs 1.7%; difference 19.8%; 95% confidence interval (CI) 8.5, 31.0; p = 0.0007; MG-QOL15: 16.1% vs 1.7%; difference 14.4%; 95% CI 4.3, 24.6; p = 0.0069].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At extension study week 130, similar proportions of patients in the eculizumab/eculizumab and placebo/eculizumab groups achieved ‘minimal symptom expression’ (MG-ADL: 22.9% and 27.8%, respectively, p = 0.7861; MG-QOL15: 14.3% and 19.4%, respectively, p = 0.7531).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consensus definition of adequately controlled generalized myasthenia gravis
“Adequately controlled gMG was defined as achieving Myasthenia Gravis Foundation of America Post-Intervention Status classification of clinical stable remission, pharmacologic remission, or minimal manifestations stable for a year; having an MG-ADL score ≤2; experiencing no clinical exacerbations during the last year requiring a change in immunosuppressive therapy or rescue therapy; and having no or mild AE to therapies (100% of experts in agreement or total agreement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expected effect sizes of FcRn inhibitors, C5 inhibitors, and CD19 B-cell depletion on MG-ADL and QMG: 27 placebo-controlled randomized trials
“Of 4,823 eligible studies, 27 placebo-controlled randomized trials (placebo n = 1,086; treatment n = 1,232) were included that targeted B cells, neonatal Fc receptor (FcRn), complement activity, CD40, and interleukin-6 signaling, as well as immunoglobulin G and broad immunosuppression therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to those treated with placebo and standard of care, QMG scores decreased by an average of -3.63 (95% credible interval -4.43 to -2.77) points more in patients treated with FcRn inhibitors, -2.59 (-3.92 to -1.28) points more in patients treated with C5 complement inhibitors (C5i), and -2.50 (-5.11 to 0.12) points more in patients treated with CD19+ B-cell depletion therapy (BCDT). The MG-ADL treatment effects were -1.93 (-2.21 to -1.65) for FcRn inhibitors, -1.84 (-2.48 to -1.19) for C5i, and -1.91 (-2.97 to -0.84) for CD19+ BCDT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“FcRn inhibitors, C5i, and CD19+ BCDT showed comparable efficacy in terms of QMG and MG-ADL reduction because meaningful differences were not observed between treatment classes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Number needed to treat for 3-point and 5-point MG-ADL and QMG improvements: analysis funded by Argenx
“Efgartigimod IV had the lowest NNT versus placebo for achieving a ≥ 3- and ≥ 5-point reduction in QMG, as well as a ≥ 5-point reduction in MG-ADL, whereas rozanolixizumab had the lowest NNT for a ≥ 3-point reduction in MG-ADL. The NNH versus placebo was similar across comparator treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by Argenx.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote